

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/07747 A1

(51) International Patent Classification⁷: **A61K 38/00**,
C12N 9/12, C12Q 1/48

(21) International Application Number: PCT/US01/22347

(22) International Filing Date: 17 July 2001 (17.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/219,244 18 July 2000 (18.07.2000) US

(71) Applicant (for all designated States except US): **JOSLIN
DIABETES CENTER, INC.** [US/US]; One Joslin Place,
Boston, MA 02115 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **KING, George, Liang**
[US/US]; 101 Sentre Street, Dover, MA 02030 (US).

(74) Agents: **MYERS, P., Louis et al.**; Fish & Richardson P.C.,
225 Franklin Street, Boston, MA 02110-2804 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

BEST AVAILABLE COPY

WO 02/07747 A1

(54) Title: METHODS OF MODULATING FIBROSIS

(57) Abstract: The invention features method fo modulating fibrosis and/or angiogenesis by inhibiting components of the VEGF signaling pathway. The methods are useful in the treatment of fibrotic and or angiogenesis related disorders.

METHODS OF MODULATING FIBROSIS

Related Applications

This application claims the benefit of U.S. Provisional application No. 60/219,244, filed on July 18, 2000, the contents of which are incorporated herein by reference in their entirety.

Federally Sponsored Research Or Development

The U.S. Government may have certain rights in this invention pursuant to Grant No. EY5110 awarded by the National Institutes of Health to George L. King.

Background

Angiogenesis and fibrosis are key components in development, growth, wound healing, and regeneration (Klagsbrun & D'Amore, (1991) *Annu. Rev. Physiol.* 53, 217-239). In addition, these processes commonly occur together in many disease states where neovascularization is believed to initiate the pathological cascade, including proliferative diabetic retinopathy (Aiello et al. (1998) *Diabetes Care* 21, 143-156), rheumatoid arthritis (Firestein (1999) *J. Clin. Invest.* 103, 3-4), and age-related macular degeneration (Lopez et al. (1996) *Invest. Ophthalmol. & Visual Sci.* 37, 855-868).

Vascular endothelial growth factor (VEGF) is expressed as a family of peptides of 121, 145, 165, 189, and 206 amino acid residues. Its expression is induced by hypoxia and is essential in the vasculogenesis process during development. Several receptors have been shown to mediate the action of VEGF, and most of them belong to the tyrosine kinase receptor family (Petrova et al. (1999) *Exp. Cell Res.* 253, 117-130). Upon the binding of VEGF to its receptors, multiple signaling cascades are activated, including the tyrosine phosphorylation of phospholipase C γ , elevation of intracellular calcium and diacylglycerol, activation of protein kinase C (PKC), and extracellular signal-regulated kinase (MAPK/ERK) for endothelial cell proliferation. In addition, VEGF also stimulates activation of phosphatidylinositol (PI) 3-kinase leading to Akt/PKB activation and possibly enhancing endothelial cell survival.

Connective tissue growth factor (CTGF) is a potent and ubiquitously expressed growth factor that has been shown to play a unique role in fibroblast proliferation, cell adhesion, and

the stimulation of extracellular matrix production (Frazier et al. (1996) *J. Invest. Dermatol.* 107, 404-411; Kireeva et al. (1997) *Exp. Cell Res.* 233, 63-77). The 38-kDa protein was originally identified in conditioned medium from human umbilical vein endothelial cells, and the expression was shown to be selectively stimulated by transforming growth factor- β (TGF- β) in cultured fibroblasts. Due to its mitogenic action on fibroblasts and its ability to induce the expression of the extracellular matrix molecules, collagen type I, fibronectin, and integrin $\alpha 5$, CTGF is supposed to play an important role in connective tissue cell proliferation and extracellular matrix deposition as one of the mediators of TGF- β . CTGF also seems to be an important player in the pathogenesis of various fibrotic disorders, since it was shown to be overexpressed in scleroderma, keloids, and other fibrotic skin disorders (Igarashi et al. (1996) *J. Invest. Dermatol.* 106, 729-733), as well as in stromal rich mammary tumors, and in advanced atherosclerotic lesions. Recently, the integrin $\alpha 5 \beta 3$ has been reported to serve as a receptor on endothelial cells for CTGF-mediated endothelial cell adhesion, migration, and angiogenesis (Babic et al. (1999) *Mol. Cell. Biol.* 19, 2958-2966).

Besides TGF- β , the expression of CTGF is reported to be regulated by dexamethasone in BALB/c 3T3 cells, high glucose in human mesangial cells, kinin in human embryonic fibroblasts, factor VIIa, and thrombin in WI-38 fibroblasts, tumor necrosis factor α in human skin fibroblast, and cAMP in bovine endothelial cells (Dammeier et al. (1998) *J. Biol. Chem.* 273, 18185-18190; Murphy et al. (1999) *J. Biol. Chem.* 274, 5830-5834; Ricupero et al. (2000) *J. Biol. Chem.* 275, 12475-12480; Pendurthi et al. (2000) *J. Biol. Chem.* 275, 14632-14641; Abraham et al. (2000) *J. Biol. Chem.* 275, 15220-15225; Boes et al. (1999) *Endocrinology* 140, 1575-1580).

Summary

The invention is based, in part, on the discovery that VEGF can regulate connective tissue growth factor (CTGF), e.g., through the PI3 Kinase-Akt pathway. CTGF is a potent diffusible growth factor which regulates extracellular matrix deposition and connective tissue cell proliferation. CTGF is a potent activator of fibrosis, angiogenesis, and extracellular matrix production. Modulation of the levels of CTGF via the VEGF pathway, e.g., by modulation of a VEGF activity, e.g., a VEGF signaling activity, e.g., a VEGF receptor (VEGFR) activity, e.g., KDR/flk1, Flt1, Flt 4, neuropilin-1 (NP-1), tie, or tie2 activity;

modulation of PI3-kinase; or modulation of Akt can thereby stimulate or alternatively reduce fibrosis and/or angiogenesis. Accordingly, one aspect of the invention features methods of modulating fibrosis. Another aspect features methods of modulating angiogenesis.

In one aspect, the invention features a method of decreasing fibrosis in a tissue, e.g., a skin, lung, retinal, renal, cardiac, or liver tissue of a subject, e.g., a human or non-human animal, by decreasing CTGF activity or expression. CTGF activity or expression is decreased by decreasing a VEGF signaling activity. In a preferred embodiment, the method includes identifying a subject in need of decreased fibrosis, e.g., a subject having a fibrotic disorder, e.g., a disorder described herein.

In a preferred embodiment, VEGF signaling is decreased by administering an agent that inhibits a component of the VEGF signal transduction pathway, e.g., an agent that decreases VEGF activity, decreases VEGF receptor (VEGFR) activity, e.g., KDR/flk1, Flt1, Flt4, NP-1, tie, or tie2 activity; decreases PI3-kinase activity; decreases an Akt activity; decreases an Erk activity.

In a preferred embodiment, KDR, Flt-4, Flt-1 or neuropilin activity is decreased.

In a preferred embodiment, the subject has a disorder related to unwanted or excessive fibrosis. In some embodiments, fibrosis is exhibited in, e.g., skin, liver, kidney, cardiac, or lung tissue. The disorder can be caused by scarring, e.g., keloid formation. Examples of other disorders related to unwanted or excessive fibrosis include, but are not limited to, scleroderma (e.g., morphea, generalized morphea, linear scleroderma); keloids; kidney fibrosis, e.g., glomerular sclerosis or renal tubulointerstitial fibrosis; pulmonary fibrosis, e.g., diffuse interstitial pulmonary fibrosis; cardiac fibrosis; chemotherapy/radiation induced lung fibrosis; pancreatitis; a disease of the kidney, e.g., glomerular sclerosis, renal tubulointerstitial fibrosis, or progressive renal disease; atherosclerotic plaques, e.g., restenosis; inflammatory bowel disease; Crohn's disease; arthritic joints, e.g., rheumatoid arthritis; cancer, e.g., invasive breast carcinoma, stromal rich mammary tumors, dermatofibromas, angioliipoma, and angioleiomyoma; hypertrophic scar; nodular fasciitis, eosinophilic fasciitis, dupuytren's contracture; macular degeneration, e.g., age-related macular degeneration; acute ocular neovascularization or diabetic retinopathy; general fibrosis syndrome, characterized by replacement of normal muscle tissue by fibrous tissue in varying degrees; retroperitoneal

fibrosis; liver fibrosis; acute fibrosis, e.g., in response to various forms of trauma including accidental injuries, infections, surgery, burns, radiation or chemotherapy treatments; or macular degeneration, e.g., age-related macular degeneration;

The method includes administering an agent which decreases CTGF activity or expression. In a preferred embodiment, the agent is an agent described herein that decreases a VEGF signaling activity.

In a preferred embodiment, CTGF activity or expression is decreased in an endothelial cell.

In a preferred embodiment, CTGF activity or expression is decreased in a pericyte.

An agent which decreases CTGF activity can be one or more of: an agent which decreases the level or activity of VEGF, e.g., an agent which inhibits VEGF interaction with a VEGF receptor (VEGFR), e.g., flt4, fltl, NP-1 tie, tie-2, and/or KDR/flk1; an agent which inhibits VEGF receptor activation; an agent which disrupts a VEGF-VEGFR complex; an agent which inhibits PI3 Kinase activity; an agent that inhibits VEGFR binding to p85, the catalytic subunit of PI3 kinase; an agent which inhibits AKT kinase activity.

In a preferred embodiment, VEGF is inhibited. VEGF can be inhibited by administering an agent which inhibits VEGF gene expression, protein production levels and/or activity. An agent which inhibits VEGF can be one or more of: a VEGF binding protein, e.g., a soluble VEGF binding protein, e.g., the ectodomain of a VEGF-receptor; an antibody that specifically binds to the VEGF protein, e.g., an antibody that disrupts VEGF's ability to bind to its natural cellular target, e.g., disrupts VEGF's ability to bind to a VEGF receptor, e.g., Fltl (VEGFR1), Flkl/KDR (VEGFR2), NP-1, tie, tie-2, or Flt4 (VEGFR3); an antibody that disrupts the ability of a VEGF receptor to bind to VEGF; an antibody or small molecule which disrupts a complex formed by VEGF and its receptor; a mutated inactive VEGF or fragment which binds to a VEGF receptor but does not activate the receptor; a VEGF nucleic acid molecule which can bind to a cellular VEGF nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or VEGF ribozyme; an agent which decreases VEGF gene expression, e.g., a small molecule which binds the promoter of VEGF. In another preferred embodiment, VEGF is inhibited by decreasing the level of expression of an endogenous VEGF gene, e.g., by decreasing transcription of the VEGF gene. In a preferred embodiment, transcription of the VEGF gene can be decreased by: altering the regulatory sequences of the endogenous VEGF gene, e.g., by the

addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator). In another preferred embodiment, the antibody which binds VEGF is a monoclonal antibody, e.g., a humanized chimeric or human monoclonal antibody.

In a preferred embodiment, VEGF interaction with its receptor is inhibited. An agent which inhibits a VEGF receptor, e.g., Flt1 (VEGFR1), Flk1/KDR (VEGFR2), neuropilin-1, tie, tie-2, or Flt4 (VEGFR3), can be one or more of: a VEGF receptor nucleic acid molecule which can bind to a cellular VEGF receptor nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or VEGF receptor ribozyme; an agent which decreases VEGF receptor gene expression, e.g., a small molecule which binds the promoter of a VEGF receptor. In another preferred embodiment, a VEGF receptor is inhibited by decreasing the level of expression of an endogenous VEGF receptor gene, e.g., by decreasing transcription of an VEGF receptor gene. In a preferred embodiment, transcription of a VEGF receptor gene can be decreased by: altering the regulatory sequences of an endogenous VEGF receptor gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA binding site for a transcriptional activator); as well as agents described above.

In a preferred embodiment, PI3 kinase is inhibited. An agent which inhibits PI3-kinase activity can be one or more of: a small molecule which inhibits PI3-kinase activity, e.g., LY294002; a protein or peptide that inhibits PI3 kinase activity, e.g., a PI3 kinase binding protein which binds to PI3-kinase but does not activate the enzyme, or a dominant negative form of p85; an antibody that specifically binds to the PI3-kinase protein, e.g., an antibody that disrupts PI3-kinase's catalytic activity or an antibody that disrupts the ability of cellular receptors to activate PI3-kinase; a PI3 kinase nucleic acid molecule which can bind to a cellular PI3 kinase nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or PI3-kinase ribozyme; an agent which decreases PI3-kinase gene expression, e.g., a small molecule which binds the promoter of PI3-kinase. In another preferred embodiment, PI3-kinase is inhibited by decreasing the level of expression of an endogenous PI3-kinase gene, e.g.,

by decreasing transcription of the PI3-kinase gene. In a preferred embodiment, transcription of the PI3-kinase gene can be decreased by: altering the regulatory sequences of the endogenous PI3-kinase gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator). In another preferred embodiment, PI3-kinase activity is inhibited by a specific small molecule inhibitor, e.g., wortmannin or LY294002.

In another preferred embodiment, AKT kinase is inhibited. An agent which inhibits AKT kinase activity can be one or more of: a specific small molecule which inhibits AKT activity; an AKT binding protein which binds to AKT but does not activate the enzyme; an antibody that specifically binds to the AKT protein, e.g., an antibody that disrupts AKT's catalytic activity or an antibody that disrupts the ability of the AKT PH domain to sense activating second messengers, e.g., phosphoinositides; a mutated inactive AKT or fragment which binds to a AKT receptor but does not activate the receptor; an AKT nucleic acid molecule which can bind to a cellular AKT nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or AKT ribozyme; an agent which decreases AKT gene expression, e.g., a small molecule which binds the promoter of AKT. In another preferred embodiment, AKT is inhibited by decreasing the level of expression of an endogenous AKT gene, e.g., by decreasing transcription of the AKT gene. In a preferred embodiment, transcription of the AKT gene can be decreased by: altering the regulatory sequences of the endogenous AKT gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator).

In one embodiment, increasing a PKC activity, e.g., a PKC α , PKC β 1, PKC β 2, or PKC γ activity, can inhibit PI3 kinase or Akt, thus decreasing CTGF expression or activity. The agent which increases the level of PKC activity can be one or more of the following: a small molecule which stimulates PKC activity, e.g., PMA; a PKC polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a PKC polypeptide or functional fragment or analog thereof; an agent which increases PKC nucleic acid expression; e.g., a small molecule which binds to the promoter region of PKC. In a preferred embodiment, PKC levels are

increased by administering, e.g., introducing, a nucleotide sequence encoding a PKC polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a PKC coding region; a promoter sequence, e.g., a promoter sequence from a PKC gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from a PKC gene or from another gene, a 3'UTR, e.g., a 3'UTR from a PKC gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of PKC protein is increased by increasing the level of expression of an endogenous PKC gene, e.g., by increasing transcription of the PKC gene. In a preferred embodiment, transcription of the PKC gene is increased by: altering the regulatory sequence of the endogenous PKC gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the PKC gene to be transcribed more efficiently.

In another preferred embodiment, Erk kinase is inhibited. An agent which inhibits Erk kinase activity can be one or more of: a specific small molecule which inhibits Erk activity; a Erk binding protein which binds to Erk but does not activate the enzyme; an antibody that specifically binds to the Erk protein, e.g., an antibody that disrupts Erk's catalytic activity; a mutated inactive Erk or fragment which binds to a Erk receptor but does not activate the receptor; a Erk nucleic acid molecule which can bind to a cellular Erk nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or Erk ribozyme; an agent which decreases Erk gene expression, e.g., a small molecule which binds the promoter of Erk. In another preferred embodiment, Erk is inhibited by decreasing the level of expression of an endogenous Erk gene, e.g., by decreasing transcription of the Erk gene. In a preferred embodiment, transcription of the Erk gene can be decreased by: altering the regulatory sequences of the endogenous Erk gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator).

Another aspect of the invention features methods of reducing angiogenesis by decreasing CTGF activity or expression. CTGF activity or expression is decreased by decreasing a VEGF signaling activity by any of the methods described herein. In preferred embodiments, angiogenesis is reduced to, e.g., treat a disorder related to excessive angiogenesis, e.g., tumor growth, tumor metastasis, arthritis, retinal neovascular disease, and retinal ischemia. The method includes administering an agent which decreases CTGF transcription or activity by inhibiting a component of the VEGF signaling pathway, e.g., by any of the agents mentioned above.

Another aspect of the invention features methods of increasing fibrosis.

In a preferred embodiment, the invention features a method of treating disorders related to insufficient fibrosis. The disorder can be the result of an injury. The disorder can be due to a genetic deficiency, a second physiological disorder or disease, or an environmental insult. In a preferred embodiment, the disorder is a wound. In another preferred embodiment the disorder is a damaged organ, e.g., an organ undergoing regeneration. The method includes administering an agent which increases the level of CTGF transcription.

An agent which increases the level of CTGF transcription can be one or more of: an agent which increases the level or activity of VEGF, e.g., a transition metal ion, e.g., manganese, cobalt, nickel, or combinations thereof; an agent which activates the VEGF receptor; an agent which increases PI3 Kinase activity; an agent which increases AKT kinase activity.

In a preferred embodiment, VEGF is increased. An agent which increases the level of VEGF activity can be one or more of the following; a small molecule, e.g., a transition metal ion; a peptide or protein, e.g., a monoclonal antibody, which stabilizes or assists the binding of VEGF to a VEGF receptor; a VEGF polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a VEGF polypeptide or functional fragment or analog thereof; an agent which increases VEGF nucleic acid expression; e.g., a small molecule which binds to the promoter region of VEGF. In a preferred embodiment, VEGF levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a VEGF polypeptide or

functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a VEGF coding region; a promoter sequence, e.g., a promoter sequence from a VEGF gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5' untranslated region (UTR), e.g., a 5'UTR from a VEGF gene or from another gene, a 3' UTR, e.g., a 3'UTR from a VEGF gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of VEGF protein is increased by increasing the level of expression of an endogenous VEGF gene, e.g., by increasing transcription of the VEGF gene. In a preferred embodiment, transcription of the VEGF gene is increased by: altering the regulatory sequence of the endogenous VEGF gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the VEGF gene to be transcribed more efficiently.

In a preferred embodiment, the VEGF receptor activity is increased. An agent which increases the level of VEGF receptor activity can be one or more of the following: an agent which activates a VEGF receptor, e.g., a monoclonal antibody which activates the VEGF receptor, e.g., a monoclonal antibody which activates a VEGF receptor in the absence of VEGF; a VEGF receptor ligand polypeptide (e.g., VEGF or placenta growth factor (PlGF)), or a functional fragment or analog thereof; a nucleotide sequence encoding a VEGF receptor polypeptide or functional fragment or analog thereof; an agent which increase VEGF receptor nucleic acid expression; e.g., a small molecule which binds to the promoter region of VEGF receptor. In a preferred embodiment, VEGF receptor levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a VEGF receptor polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a VEGF receptor coding region; a promoter sequence, e.g., a promoter sequence from a VEGF receptor gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5' untranslated region (UTR), e.g., a 5'UTR from a VEGF receptor

gene or from another gene, a 3'UTR, e.g., a 3'UTR from a VEGF receptor gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of VEGF receptor protein is increased by increasing the level of expression of an endogenous VEGF receptor gene, e.g., by increasing transcription of the VEGF receptor gene. In a preferred embodiment, transcription of the VEGF receptor gene is increased by: altering the regulatory sequence of the endogenous VEGF receptor gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the VEGF receptor gene to be transcribed more efficiently.

In a preferred embodiment, PI3-Kinase is increased. An agent which increases the level of PI3-kinase can be one or more of the following: a small molecule which activates PI3kinase; a PI3kinase polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a PI3kinase polypeptide or functional fragment or analog thereof; an agent which increase PI3-kinase nucleic acid expression, e.g., a small molecule which binds to the promoter region of PI3 kinase. In a preferred embodiment, PI3-kinase levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a PI3-kinase polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a PI3-kinase coding region; a promoter sequence, e.g., a promoter sequence from a PI3 kinase gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from a PI3kinase gene or from another gene, a 3'UTR, e.g., a 3'UTR from a PI3-kinase gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of PI3kinase protein is increased by increasing the level of expression of an endogenous PI3-kinase gene, e.g., by increasing transcription of the PI3-kinase gene. In a preferred embodiment, transcription of the PI3-kinase gene is increased by: altering the regulatory sequence of the endogenous PI3 kinase gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator);

the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the PI3-kinase gene to be transcribed more efficiently.

In a preferred embodiment, AKT is increased. An agent which increases the level of AKT can be one or more of the following: a small molecule which activates AKT kinase activity, e.g., the phosphoinositide PIP₂; a polypeptide, e.g., insulin, which stimulates activation, e.g., phosphorylation, of AKT; a AKT polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a AKT polypeptide or functional fragment or analog thereof; an agent which increase AKT nucleic acid expression; e.g., a small molecule which binds to the promoter region of AKT. In a preferred embodiment, AKT levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a AKT polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a AKT coding region; a promoter sequence, e.g., a promoter sequence from a AKT gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from a AKT gene or from another gene, a 3'UTR, e.g., a 3'UTR from a AKT gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of AKT protein is increased by increasing the level of expression of an endogenous AKT gene, e.g., by increasing transcription of the AKT gene. In a preferred embodiment, transcription of the AKT gene is increased by: altering the regulatory sequence of the endogenous AKT gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the AKT gene to be transcribed more efficiently.

In another preferred embodiment, Erk kinase is increased. An agent which increases Erk kinase activity can be one or more of: a small molecule which activates Erk kinase activity; an Erk polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding

an Erk polypeptide or functional fragment or analog thereof; an agent which increases Erk nucleic acid expression; e.g., a small molecule which binds to the promoter region of Erk. In a preferred embodiment, Erk levels are increased by administering, e.g., introducing, a nucleotide sequence encoding an Erk polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: an Erk coding region; a promoter sequence, e.g., a promoter sequence from an Erk gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from an Erk gene or from another gene, a 3'UTR, e.g., a 3'UTR from an Erk gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of Erk protein is increased by increasing the level of expression of an endogenous Erk gene, e.g., by increasing transcription of the Erk gene. In a preferred embodiment, transcription of the Erk gene is increased by: altering the regulatory sequence of the endogenous Erk gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the Erk gene to be transcribed more efficiently.

Another aspect of the invention features a method of screening for agents which increase or decrease fibrosis and/or angiogenesis to thereby treat disorders associated with increased or decreased fibrosis, e.g., the disorders mentioned above. The method includes: providing a cell, tissue, or subject, e.g., an experimental animal, e.g., an animal model for a fibrosis related disorder; contacting the cell, tissue or subject with a test agent; and determining whether the test agent inhibits a component of the VEGF signaling pathway.

In preferred embodiments, the screening can include screening for: an agent that inhibits VEGF activity; an agent that inhibits VEGFR signaling, e.g., an agent that inhibits the interaction between VEGF and a VEGFR; an agent that inhibits PI3 kinase activity; an agent that inhibits a VEGFR interaction with p85 subunit of PI3-kinase; an agent that inhibits AKT activity; and/or an agent that inhibits ERK activity.

In some embodiments, the method can include one or more of the following steps:

applying VEGF to cells in culture, e.g., BREC or BREP; applying a candidate drug or a combinatorial library of drugs; assaying for levels of CTGF. CTGF levels can be assayed various methods commonly practiced in the art. In one embodiment, CTGF levels are assayed by Northern analysis for CTGF mRNA expression. In another embodiment CTGF levels are assayed by detect CTGF protein, e.g., with an antibody, e.g., using an ELISA assay or a Western blot assay. In another embodiment, CTGF transcription is monitored by assaying for a reporter protein, e.g., lacZ, chloramphenicol acetyltransferase (CAT), green fluorescent protein or variants thereof, and other fluorescent proteins and variants thereof, where the gene encoding the reporter protein is fused to the CTGF promoter and the ensemble is transfected into the cells. The methods can further include administering an agent identified by the screening methods described herein to an animal, e.g., an animal model for a fibrotic disorder.

Detailed Description

The inventors have discovered that VEGF can modulate the activity and/or expression of CTGF in a time- and concentration-dependent manner in cells and/or tissues with VEGF receptors, e.g., in endothelial cells, e.g., microvascular endothelial cells such as human retinal endothelial cells or bovine retinal endothelial cells (BREC), and in contractile cells, e.g., in capillary pericytes, e.g., in human or bovine retinal pericytes (BRPC). VEGF-induced modulation of CTGF can occur via the PI3 kinase pathway, e.g., via the KDR receptor-PI3 kinase-Erk pathway (e.g., in BREC), or the Flt1-PI3 kinase-Akt pathway (e.g., in BRPC). Modulation of CTGF via the VEGF pathway can be used to modulate fibrosis and/or angiogenesis, e.g., in the treatment of fibrosis-related disorders described herein.

VEGF receptor (VEGFR), e.g., Flt1 (VEGFR1), KDR/Flk1 (VEGFR2), Flt4 (VEGFR3), NP1, tie, or tie-2, can mediate increases in CTGF mRNA expression. The ability of Flt1 to induce increases in CTGF mRNA levels is demonstrated in the pericytes that have predominantly Flt1 receptors. In addition, placenta growth factor (PlGF), a Flt1 receptor-specific ligand, was able to induce CTGF mRNA levels in BRPC but not in BREC, indicating that VEGF can induce CTGF mRNA by activating through Flt1 in pericytes, e.g., BRPC. The KDR/Flk1 receptors in the endothelial cells can also induce CTGF gene expression since KDR/Flk1 receptors are the predominant VEGF receptors in endothelial cells.

The VEGF dose-response curves for CTGF in both BRPC and BREC are similar and

suggest that VEGF binds to high affinity receptors, consistent with the known K_d values of Flt1 and KDR/Flk1 at 10-100 pM. While not wanting to be bound by theory, VEGF-induced CTGF mRNA is most likely due to an induction of transcription rather than altering the half-life of CTGF mRNA since the addition of VEGF failed to change the degradation rates of CTGF mRNA. The time course of the action of VEGF on CTGF (which required 6-9 h) suggests this is potentially a chronic action of VEGF. In addition, the time needed to achieve maximum effect is also consistent with the calculated mRNA half-life of CTGF mRNA of 2-4 h.

From a biological perspective, the effects of VEGF on CTGF mRNA could potentially have important physiological impact for several reasons. First, the increase in CTGF mRNA results in increased protein levels. Second, the VEGF concentration that was minimally active (0.25 ng/ml) can easily bind and activate a significant percentage of the VEGFR-1, -2 receptors. Third, this low level of VEGF may exist even in non-pathological states, suggesting that low levels of VEGF may have physiological actions on maintaining extracellular matrix production via the induction of CTGF. At 2.5-25 ng/ml VEGF which are encountered in hypoxic and angiogenic states (Aiello et al. (1994) *N. Engl. J. Med.* 331, 1480-1487), the induction of CTGF expression by VEGF could potentially induce the fibrosis that frequently accompanies neovascularization. This possibility is supported further by the demonstration that the protein levels of CTGF expression were increased 10 h after the addition of VEGF that was consistent with the maximum increase in the mRNA levels at 6-9 h. In addition, the potency of VEGF on CTGF expression appeared to be similar to TGF-beta1, suggesting that both of them could induce fibrosis associated with neovascularization.

The activation of the endogenous tyrosine kinases of KDR/Flk1s can stimulate multiple signaling pathways, including Ras-Erk, PI3-kinase-Akt, and phospholipase CK-PKC cascades. The results in BREC described herein indicate that VEGF can increase the tyrosine phosphorylation of KDR/Flk1 and its interaction with p85 subunit of PI3-kinase. In addition, VEGF also activates the Erk1/2 pathway in BREC. In contrast, VEGF was unable to activate Erk1/2 but stimulated the activation of PI3-kinase and phosphorylation of Akt in BRPC. These results indicate that the signaling pathways for Flt1 in vascular cells are different from those for KDR/Flk1. The lack of effect on Erk1/2 activation also supports the hypothesis that Flt1, unlike KDR/Flk1, is not involved in mitogenic actions.

The results described herein provide strong evidence that VEGF is inducing CTGF gene

expression in both endothelial cells and pericytes via VEGFR1 or -R2 by the activation of PI3-kinase and Akt. This evidence includes the ability of wortmannin, a PI3-kinase inhibitor, to inhibit the effects of VEGFs in both cell types. Adenovirus containing dominant negative mutants of p85 subunit of PI3-kinase or Akt inhibited the action of VEGFs, whereas overexpression of dominant negative mutants of Ras and Erk1 by adenovirus vectors did not inhibit CTGF mRNA expression. Conversely, the overexpression of constitutive active Akt increased CTGF mRNA expression by 2.5-fold. The overexpression of either the wild type or dominant negative of PKC isoform did not alter the effects of VEGF on CTGF mRNA levels.

In summary, the results described herein show that VEGF can induce the expression of CTGF via VEGFR, e.g., Flt1, KDR/Flk1, Flt4, NP-1, tie, or tie-2, by the selectively activated PI3-kinase-Akt pathway but mostly independent of the Ras-Erk pathway. In addition, the spectrum of signaling pathways can be different among different VEGFRs, possibly reflecting their physiological roles. These results support the conclusion that VEGF, through its effects on CTGF expression, has physiological roles such as the maintenance of capillary strength and wound healing via the extracellular matrix production. In disease states, VEGF-induced CTGF may cause the proliferation of fibrocellular components in retinal neovascular diseases such as proliferative diabetic retinopathy and age-related macular degeneration.

Modulation of CTGF through the VEGF pathway, e.g., modulation of components of the VEGF pathway, e.g., Flt1, KDR, Flt4, neuropilin-1, PI3 kinase, Akt, or Erk, can be used to modulate fibrosis and/or angiogenesis, e.g., in the treatment of fibrosis related disorders. CTGF has been associated with a number of fibrosis-related disorders, e.g., scleroderma (e.g., morphea, generalized morphea, linear scleroderma); keloids; kidney fibrosis, e.g., glomerular sclerosis or renal tubulointerstitial fibrosis; pulmonary fibrosis; cardiac fibrosis; chemotherapy/radiation induced lung fibrosis; pancreatitis; renal disease; atherosclerotic plaques; inflammatory bowel disease; Crohn's disease; arthritic joints; cancer, e.g., invasive breast carcinoma, dermatofibromas, angiolipoma, and angioleiomyoma; hypertrophic scar; nodular fasciitis, eosinophilic fasciitis, dupuytren's contracture (*J. Invest. Dermatol.* 1996 106:729-733; *J Biol Chem.* 2001 276:10594-601; *Int J Biochem Cell Biol.* 1998 30:909-22; *J Eur Acad Dermatol Venereol.* 1998 11:1-8; *Int J Biochem Cell Biol.* 1998 Aug;30(8):909-22;

Ann Surg. 1999 Jul;230(1):63-71; J Cell Physiol. 1999 Oct;181(1):153-9; Curr Opin Nephrol Hypertens. 1999 Sep;8(5):543-8; J Am Soc Nephrol. 2001 Mar;12(3):472-84; J Rheumatol. 2000 Jan;27(1):149-54; J Mol Cell Cardiol. 2000 Oct;32(10):1805-19). Other fibrosis related diseases in which CTGF may be involved include macular degeneration, e.g., age-related macular degeneration; acute ocular neovascularization or diabetic retinopathy; general fibrosis syndrome, characterized by replacement of normal muscle tissue by fibrous tissue in varying degrees; retroperitoneal fibrosis; liver fibrosis; acute fibrosis, e.g., in response to various forms of trauma including accidental injuries, infections, surgery, burns, radiation or chemotherapy treatments.

Generation of Fragments

Fragments of components of the VEGF signaling pathway, e.g., VEGF, VEGFRs, PI3 kinase, AKT, can be used to increase VEGF signaling, thereby increasing CTGF activity, thereby increasing fibrosis or angiogenesis. For example, various fragments of VEGF are known and described, for example, in U.S. Patent No.: 5,935,820.

Fragments of a protein can be produced in several ways, e.g., recombinantly, by proteolytic digestion, or by chemical synthesis. Internal or terminal fragments of a polypeptide can be generated by removing one or more nucleotides from one end (for a terminal fragment) or both ends (for an internal fragment) of a nucleic acid which encodes the polypeptide. Expression of the mutagenized DNA produces polypeptide fragments. Digestion with "end-nibbling" endonucleases can thus generate DNA's which encode an array of fragments. DNA's which encode fragments of a protein can also be generated by random shearing, restriction digestion or a combination of the above-discussed methods.

Fragments can also be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. For example, peptides of the present invention may be arbitrarily divided into fragments of desired length with no overlap of the fragments, or divided into overlapping fragments of a desired length.

Generation of Analogs: Production of Altered DNA and Peptide Sequences by Random Methods

Amino acid sequence variants of a protein, e.g., a VEGF signaling pathway component described herein, can be prepared by random mutagenesis of DNA which encodes a protein or a

particular domain or region of a protein. Useful methods include PCR mutagenesis and saturation mutagenesis. A library of random amino acid sequence variants can also be generated by the synthesis of a set of degenerate oligonucleotide sequences. (Methods for screening proteins in a library of variants, e.g., screening for CTGF modulating activity or VEGF signaling agonist or antagonist activity, are elsewhere herein.)

PCR Mutagenesis

In PCR mutagenesis, reduced Taq polymerase fidelity is used to introduce random mutations into a cloned fragment of DNA (Leung et al., 1989, *Technique* 1:11-15). This is a very powerful and relatively rapid method of introducing random mutations. The DNA region to be mutagenized is amplified using the polymerase chain reaction (PCR) under conditions that reduce the fidelity of DNA synthesis by Taq DNA polymerase, e.g., by using a dGTP/dATP ratio of five and adding Mn^{2+} to the PCR reaction. The pool of amplified DNA fragments are inserted into appropriate cloning vectors to provide random mutant libraries.

Saturation Mutagenesis

Saturation mutagenesis allows for the rapid introduction of a large number of single base substitutions into cloned DNA fragments (Mayers et al., 1985, *Science* 229:242). This technique includes generation of mutations, e.g., by chemical treatment or irradiation of single-stranded DNA *in vitro*, and synthesis of a complementary DNA strand. The mutation frequency can be modulated by modulating the severity of the treatment, and essentially all possible base substitutions can be obtained. Because this procedure does not involve a genetic selection for mutant fragments both neutral substitutions, as well as those that alter function, are obtained. The distribution of point mutations is not biased toward conserved sequence elements.

Degenerate Oligonucleotides

A library of homologs can also be generated from a set of degenerate oligonucleotide sequences. Chemical synthesis of a degenerate sequences can be carried out in an automatic DNA synthesizer, and the synthetic genes then ligated into an appropriate expression vector. The synthesis of degenerate oligonucleotides is known in the art (see for example, Narang, SA (1983) *Tetrahedron* 39:3; Itakura et al. (1981) *Recombinant DNA, Proc 3rd Cleveland Sympos.*

Macromolecules, ed. AG Walton, Amsterdam: Elsevier pp273-289; Itakura et al. (1984) *Ann. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477. Such techniques have been employed in the directed evolution of other proteins (see, for example, Scott et al. (1990) *Science* 249:386-390; Roberts et al. (1992) *PNAS* 89:2429-2433; Devlin et al. (1990) *Science* 249: 404-406; Cwirla et al. (1990) *PNAS* 87: 6378-6382; as well as U.S. Patents Nos. 5,223,409, 5,198,346, and 5,096,815).

Generation of Analogs: Production of Altered DNA and Peptide Sequences by Directed Mutagenesis

Non-random or directed, mutagenesis techniques can be used to provide specific sequences or mutations in specific regions. These techniques can be used to create variants which include, e.g., deletions, insertions, or substitutions, of residues of the known amino acid sequence of a protein. The sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conserved amino acids and then with more radical choices depending upon results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.

Alanine Scanning Mutagenesis

Alanine scanning mutagenesis is a useful method for identification of certain residues or regions of the desired protein that are preferred locations or domains for mutagenesis, Cunningham and Wells (*Science* 244:1081-1085, 1989). In alanine scanning, a residue or group of target residues are identified (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyaniline). Replacement of an amino acid can affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensitivity to the substitutions are then refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, alanine scanning or random mutagenesis may be conducted at the target codon or region and the expressed desired protein subunit variants are screened for the optimal combination of desired activity.

Oligonucleotide-Mediated Mutagenesis

Oligonucleotide-mediated mutagenesis is a useful method for preparing substitution, deletion, and insertion variants of DNA, see, e.g., Adelman et al., (*DNA* 2:183, 1983). Briefly, the desired DNA is altered by hybridizing an oligonucleotide encoding a mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of the desired protein. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the desired protein DNA. Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al. (*Proc. Natl. Acad. Sci.* (1978) USA, 75: 5765).

Cassette Mutagenesis

Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells et al. (*Gene*, 34:315[1985]). The starting material is a plasmid (or other vector) which includes the protein subunit DNA to be mutated. The codon(s) in the protein subunit DNA to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, they may be generated using the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in the desired protein subunit DNA. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have 3' and 5' ends that are comparable with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid. This plasmid now contains the mutated desired protein subunit DNA sequence.

Combinatorial Mutagenesis

Combinatorial mutagenesis can also be used to generate mutants. For example, the amino acid sequences for a group of homologs or other related proteins are aligned, preferably to promote the highest homology possible. All of the amino acids which appear at a given position of the aligned sequences can be selected to create a degenerate set of combinatorial sequences. The variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level, and is encoded by a variegated gene library. For example, a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential sequences are expressible as individual peptides, or alternatively, as a set of larger fusion proteins containing the set of degenerate sequences.

Primary High-Through-Put Methods for Screening Libraries of Peptide Fragments or Homologs

Various techniques are known in the art for screening generated mutant gene products. Techniques for screening large gene libraries often include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the genes under conditions in which detection of a desired activity, assembly into a trimeric molecules, binding to natural ligands, e.g., a receptor or substrates, facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the techniques described below is amenable to high through-put analysis for screening large numbers of sequences created, e.g., by random mutagenesis techniques.

Two Hybrid Systems

Two hybrid (interaction trap) assays can be used to identify a protein that interacts with a component of the VEGF signaling pathway, e.g., VEGF, VEGFR (e.g., flt1, flt4, KDR, neuropilin), PI3 kinase (e.g., p85), AKT, ERK. These may include agonists, superagonists, and antagonists of the components. (The subject protein and a protein it interacts with are used as the bait protein and fish proteins.). These assays rely on detecting the reconstitution of a functional transcriptional activator mediated by protein-protein interactions with a bait protein. In particular, these assays make use of chimeric genes which express hybrid proteins. The first hybrid comprises a DNA-binding domain fused to the bait protein. e.g., a VEGF or VEGFR

molecule or a fragment thereof. The second hybrid protein contains a transcriptional activation domain fused to a "fish" protein, e.g. an expression library. If the fish and bait proteins are able to interact, they bring into close proximity the DNA-binding and transcriptional activator domains. This proximity is sufficient to cause transcription of a reporter gene which is operably linked to a transcriptional regulatory site which is recognized by the DNA binding domain, and expression of the marker gene can be detected and used to score for the interaction of the bait protein with another protein.

Display Libraries

In one approach to screening assays, the candidate peptides are displayed on the surface of a cell or viral particle, and the ability of particular cells or viral particles to bind an appropriate receptor protein via the displayed product is detected in a "panning assay". For example, the gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected by panning (Ladner et al., WO 88/06630; Fuchs et al. (1991) *Bio/Technology* 9:1370-1371; and Goward et al. (1992) *TIBS* 18:136-140). In a similar fashion, a detectably labeled ligand can be used to score for potentially functional peptide homologs. Fluorescently labeled ligands, e.g., receptors, can be used to detect homolog which retain ligand-binding activity. The use of fluorescently labeled ligands, allows cells to be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell permits, to be separated by a fluorescence-activated cell sorter.

A gene library can be expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at concentrations well over 10^{13} phage per milliliter, a large number of phage can be screened at one time. Second, since each infectious phage displays a gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical *E. coli* filamentous phages M13, fd., and f1 are most often used in phage display libraries. Either of the phage gIII or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle. Foreign epitopes can be expressed at the NH₂-terminal end of pIII and phage bearing such epitopes recovered from a large excess of phage

lacking this epitope (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) *J. Biol. Chem.* 267:16007-16010; Griffiths et al. (1993) *EMBO J* 12:725-734; Clackson et al. (1991) *Nature* 352:624-628; and Barbas et al. (1992) *PNAS* 89:4457-4461).

A common approach uses the maltose receptor of *E. coli* (the outer membrane protein, LamB) as a peptide fusion partner (Charbit et al. (1986) *EMBO* 5, 3029-3037). Oligonucleotides have been inserted into plasmids encoding the LamB gene to produce peptides fused into one of the extracellular loops of the protein. These peptides are available for binding to ligands, e.g., to antibodies, and can elicit an immune response when the cells are administered to animals. Other cell surface proteins, e.g., OmpA (Schorr et al. (1991) *Vaccines* 91, pp. 387-392), PhoE (Agterberg, et al. (1990) *Gene* 88, 37-45), and PAL (Fuchs et al. (1991) *Bio/Tech* 9, 1369-1372), as well as large bacterial surface structures have served as vehicles for peptide display. Peptides can be fused to pilin, a protein which polymerizes to form the pilus-a conduit for interbacterial exchange of genetic information (Thiry et al. (1989) *Appl. Environ. Microbiol.* 55, 984-993). Because of its role in interacting with other cells, the pilus provides a useful support for the presentation of peptides to the extracellular environment. Another large surface structure used for peptide display is the bacterial motive organ, the flagellum. Fusion of peptides to the subunit protein flagellin offers a dense array of many peptides copies on the host cells (Kuwajima et al. (1988) *Bio/Tech.* 6, 1080-1083). Surface proteins of other bacterial species have also served as peptide fusion partners. Examples include the *Staphylococcus* protein A and the outer membrane protease IgA of *Neisseria* (Hansson et al. (1992) *J. Bacteriol.* 174, 4239-4245 and Klauser et al. (1990) *EMBO J.* 9, 1991-1999).

In the filamentous phage systems and the LamB system described above, the physical link between the peptide and its encoding DNA occurs by the containment of the DNA within a particle (cell or phage) that carries the peptide on its surface. Capturing the peptide captures the particle and the DNA within. An alternative scheme uses the DNA-binding protein LacI to form a link between peptide and DNA (Cull et al. (1992) *PNAS USA* 89:1865-1869). This system uses a plasmid containing the LacI gene with an oligonucleotide cloning site at its 3'-end. Under the controlled induction by arabinose, a LacI-peptide fusion protein is produced. This fusion retains the natural ability of LacI to bind to a short DNA sequence known as LacO operator (LacO). By installing two copies of LacO on the expression plasmid, the LacI-peptide fusion binds tightly to

the plasmid that encoded it. Because the plasmids in each cell contain only a single oligonucleotide sequence and each cell expresses only a single peptide sequence, the peptides become specifically and stably associated with the DNA sequence that directed its synthesis. The cells of the library are gently lysed and the peptide-DNA complexes are exposed to a matrix of immobilized receptor to recover the complexes containing active peptides. The associated plasmid DNA is then reintroduced into cells for amplification and DNA sequencing to determine the identity of the peptide ligands. As a demonstration of the practical utility of the method, a large random library of dodecapeptides was made and selected on a monoclonal antibody raised against the opioid peptide dynorphin B. A cohort of peptides was recovered, all related by a consensus sequence corresponding to a six-residue portion of dynorphin B. (Cull et al. (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89-1869)

This scheme, sometimes referred to as peptides-on-plasmids, differs in two important ways from the phage display methods. First, the peptides are attached to the C-terminus of the fusion protein, resulting in the display of the library members as peptides having free carboxy termini. Both of the filamentous phage coat proteins, pIII and pVIII, are anchored to the phage through their C-termini, and the guest peptides are placed into the outward-extending N-terminal domains. In some designs, the phage-displayed peptides are presented right at the amino terminus of the fusion protein. (Cwirla, et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87, 6378-6382) A second difference is the set of biological biases affecting the population of peptides actually present in the libraries. The LacI fusion molecules are confined to the cytoplasm of the host cells. The phage coat fusions are exposed briefly to the cytoplasm during translation but are rapidly secreted through the inner membrane into the periplasmic compartment, remaining anchored in the membrane by their C-terminal hydrophobic domains, with the N-termini, containing the peptides, protruding into the periplasm while awaiting assembly into phage particles. The peptides in the LacI and phage libraries may differ significantly as a result of their exposure to different proteolytic activities. The phage coat proteins require transport across the inner membrane and signal peptidase processing as a prelude to incorporation into phage. Certain peptides exert a deleterious effect on these processes and are underrepresented in the libraries (Gallop et al. (1994) *J. Med. Chem.* 37(9):1233-1251). These particular biases are not a factor in the LacI display system.

The number of small peptides available in recombinant random libraries is enormous. Libraries of 10^7 - 10^9 independent clones are routinely prepared. Libraries as large as 10^{11} recombinants have been created, but this size approaches the practical limit for clone libraries. This limitation in library size occurs at the step of transforming the DNA containing randomized segments into the host bacterial cells. To circumvent this limitation, an *in vitro* system based on the display of nascent peptides in polysome complexes has recently been developed. This display library method has the potential of producing libraries 3-6 orders of magnitude larger than the currently available phage/phagemid or plasmid libraries. Furthermore, the construction of the libraries, expression of the peptides, and screening, is done in an entirely cell-free format.

In one application of this method (Gallop et al. (1994) *J. Med. Chem.* 37(9):1233-1251), a molecular DNA library encoding 10^{12} decapeptides was constructed and the library expressed in an *E. coli* S30 *in vitro* coupled transcription/translation system. Conditions were chosen to stall the ribosomes on the mRNA, causing the accumulation of a substantial proportion of the RNA in polysomes and yielding complexes containing nascent peptides still linked to their encoding RNA. The polysomes are sufficiently robust to be affinity purified on immobilized receptors in much the same way as the more conventional recombinant peptide display libraries are screened. RNA from the bound complexes is recovered, converted to cDNA, and amplified by PCR to produce a template for the next round of synthesis and screening. The polysome display method can be coupled to the phage display system. Following several rounds of screening, cDNA from the enriched pool of polysomes was cloned into a phagemid vector. This vector serves as both a peptide expression vector, displaying peptides fused to the coat proteins, and as a DNA sequencing vector for peptide identification. By expressing the polysome-derived peptides on phage, one can either continue the affinity selection procedure in this format or assay the peptides on individual clones for binding activity in a phage ELISA, or for binding specificity in a completion phage ELISA (Barret, et al. (1992) *Anal. Biochem* 204,357-364). To identify the sequences of the active peptides one sequences the DNA produced by the phagemid host.

Secondary Screens

The high through-put assays described above can be followed by secondary screens in order to identify further biological activities which will, e.g., allow one skilled in the art to differentiate agonists from antagonists. The type of a secondary screen used will depend on the

desired activity that needs to be tested. For example, an assay can be developed in which the ability to inhibit an interaction between a protein of interest (e.g., VEGF or PI3 kinase) and a ligand (e.g., VEGFR and AKT, respectively) can be used to identify antagonists from a group of peptide fragments isolated through one of the primary screens described above.

Therefore, methods for generating fragments and analogs and testing them for activity are known in the art. Once the core sequence of interest is identified, it is routine to perform for one skilled in the art to obtain analogs and fragments.

Peptide Mimetics

The invention also provides for reduction of the protein binding domains of the subject polypeptides, e.g., VEGF or VEGFR, to generate mimetics, e.g., peptide or non-peptide agents. See, for example, "Peptide inhibitors of human papillomavirus protein binding to retinoblastoma gene protein" European patent applications EP 0 412 762 and EP 0 031 080.

Non-hydrolyzable peptide analogs of critical residues can be generated using benzodiazepine (e.g., see Freidinger et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), azepine (e.g., see Huffman et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gamma lactam rings (Garvey et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al. (1986) *J Med Chem* 29:295; and Ewenson et al. in *Peptides: Structure and Function* (Proceedings of the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, IL, 1985), β -turn dipeptide cores (Nagai et al. (1985) *Tetrahedron Lett* 26:647; and Sato et al. (1986) *J Chem Soc Perkin Trans* 1:1231), and β -aminoalcohols (Gordon et al. (1985) *Biochem Biophys Res Commun* 126:419; and Dann et al. (1986) *Biochem Biophys Res Commun* 134:71).

Fusion Proteins

Polypeptides for modulating the level of a component of the VEGF signaling pathway can be fused to another protein or portion thereof. For example, a VEGF protein or antagonist or fragment thereof, can be operably linked to another polypeptide moiety to enhance solubility. Examples of a protein which can be fused with a protein or portions thereof include a plasma protein or fragment thereof, which can improve the circulating half life. For example, the fusion

protein can be a VEGF fragment-immunoglobulin (Ig) fusion protein in which the VEGF sequence is fused to a sequence derived from the immunoglobulin superfamily. Several soluble fusion protein constructs have been disclosed wherein the extracellular domain of a cell surface glycoprotein is fused with the constant F(c) region of an immunoglobulin. For example, Capon et al. (1989) *Nature* 337(9):525-531, provide guidance on generating a longer lasting CD4 analog by fusing CD4 to an immunoglobulin (IgG1). *See also*, Capon et al., U.S. Patent Numbers: 5,116,964 and 5,428,130 (CD4-IgG fusion constructs); Linsley et al., U.S. Patent Number 5,434,131 (CTLA4-IgG1 and B7-IgG1 fusion constructs); Linsley et al. (1991) *J. Exp. Med.* 174:561-569 (CTLA4-IgG1 fusion constructs); and Linsley et al. (1991) *J. Exp. Med.* 173:721-730 (CD28-IgG1 and B7-IgG1 fusion constructs). Such fusion proteins have proven useful for modulating receptor-ligand interactions and reducing inflammation *in vivo*. For example, fusion proteins in which an extracellular domain of cell surface tumor necrosis factor receptor (TNFR) proteins has been fused to an immunoglobulin constant (Fc) region have been used *in vivo*. *See, for example*, Moreland et al. (1997) *N. Engl. J. Med.* 337(3):141-147; and, van der Poll et al. (1997) *Blood* 89(10):3727-3734).

Antibodies

The invention also includes antibodies specifically reactive with a component of the VEGF signaling pathway described herein. Anti-protein/anti-peptide antisera or monoclonal antibodies can be made as described herein by using standard protocols (See, for example, *Antibodies: A Laboratory Manual* ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)).

A component of the VEGF signaling pathway described herein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind the component using standard techniques for polyclonal and monoclonal antibody preparation. The full-length component protein can be used or, alternatively, antigenic peptide fragments of the component can be used as immunogens.

Typically, a peptide is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, a recombinant VEGF peptide, or a chemically synthesized VEGF peptide or antagonist. *See, e.g.*, U.S. Patent No. 5,460,959; and co-pending U.S. applications USSN 08/334,797; USSN 08/231,439; USSN 08/334,455; and USSN 08/928,881

which are hereby expressly incorporated by reference in their entirety. The nucleotide and amino acid sequences of components of the VEGF signaling pathway described herein are known. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic VEGF preparation induces a polyclonal anti-VEGF antibody response.

Antibodies to a component of the VEGF signaling pathway, or fragments thereof, can be used to inhibit the levels of such a component, thereby decreasing CTGF activity. Examples of antibody fragments include F(v), Fab, Fab' and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope. A monoclonal antibody composition thus typically displays a single binding affinity for a particular protein with which it immunoreacts.

Additionally, antibodies produced by genetic engineering methods, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, can be used. Such chimeric and humanized monoclonal antibodies can be produced by genetic engineering using standard DNA techniques known in the art, for example using methods described in Robinson et al. International Application No. PCT/US86/02269; Akira, et al. European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al. European Patent Application 173,494; Neuberger et al. PCT International Publication No. WO 86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al. European Patent Application 125,023; Better et al., *Science* 240:1041-1043, 1988; Liu et al., *PNAS* 84:3439-3443, 1987; Liu et al., *J. Immunol.* 139:3521-3526, 1987; Sun et al. *PNAS* 84:214-218, 1987; Nishimura et al., *Canc. Res.* 47:999-1005, 1987; Wood et al., *Nature* 314:446-449, 1985; and Shaw et al., *J. Natl. Cancer Inst.* 80:1553-1559, 1988; Morrison, S. L., *Science* 229:1202-1207, 1985; Oi et al., *BioTechniques* 4:214, 1986; Winter U.S. Patent 5,225,539; Jones et al., *Nature* 321:552-525, 1986; Verhoeyan et al., *Science* 239:1534, 1988; and Beidler et al., *J. Immunol.* 141:4053-4060, 1988.

In addition, a human monoclonal antibody directed against a component of the VEGF signaling pathway described herein can be made using standard techniques. For example, human monoclonal antibodies can be generated in transgenic mice or in immune deficient mice

engrafted with antibody-producing human cells. Methods of generating such mice are describe, for example, in Wood et al. PCT publication WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741; Lonberg et al. PCT publication WO 92/03918; Kay et al. PCT publication WO 92/03917; Kay et al. PCT publication WO 93/12227; Kay et al. PCT publication 94/25585; Rajewsky et al. Pct publication WO 94/04667; Ditullio et al. PCT publication WO 95/17085; Lonberg, N. et al. (1994) *Nature* 368:856-859; Green, L.L. et al. (1994) *Nature Genet.* 7:13-21; Morrison, S.L. et al. (1994) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Bruggeman et al. (1993) *Year Immunol* 7:33-40; Choi et al. (1993) *Nature Genet.* 4:117-123; Tuailon et al. (1993) *PNAS* 90:3720-3724; Bruggeman et al. (1991) *Eur J Immunol* 21:1323-1326); Duchosal et al. PCT publication WO 93/05796; U.S. Patent Number 5,411,749; McCune et al. (1988) *Science* 241:1632-1639), Kamel-Reid et al. (1988) *Science* 242:1706; Spanopoulou (1994) *Genes & Development* 8:1030-1042; Shinkai et al. (1992) *Cell* 68:855-868). A human antibody-transgenic mouse or an immune deficient mouse engrafted with human antibody-producing cells or tissue can be immunized with a component of the VEGF signaling pathway described herein or an antigenic peptide thereof and splenocytes from these immunized mice can then be used to create hybridomas. Methods of hybridoma production are well known.

Human monoclonal antibodies against components of the VEGF signaling pathway described herein can also be prepared by constructing a combinatorial immunoglobulin library, such as a Fab phage display library or a scFv phage display library, using immunoglobulin light chain and heavy chain cDNAs prepared from mRNA derived from lymphocytes of a subject. *See, e.g.*, McCafferty et al. PCT publication WO 92/01047; Marks et al. (1991) *J. Mol. Biol.* 222:581-597; and Griffiths et al. (1993) *EMBO J* 12:725-734. In addition, a combinatorial library of antibody variable regions can be generated by mutating a known human antibody. For example, a variable region of a human antibody known to bind VEGF, can be mutated, by for example using randomly altered mutagenized oligonucleotides, to generate a library of mutated variable regions which can then be screened to bind to VEGF. Methods of inducing random mutagenesis within the CDR regions of immunoglobulin heavy and/or light chains, methods of crossing randomized heavy and light chains to form pairings and screening methods can be found in, for example, Barbas et al. PCT publication WO 96/07754; Barbas et al. (1992) *Proc. Nat'l Acad. Sci. USA* 89:4457-4461.

The immunoglobulin library can be expressed by a population of display packages, preferably derived from filamentous phage, to form an antibody display library. Examples of methods and reagents particularly amenable for use in generating antibody display library can be found in, for example, Ladner et al. U.S. Patent No. 5,223,409; Kang et al. PCT publication WO 92/18619; Dower et al. PCT publication WO 91/17271; Winter et al. PCT publication WO 92/20791; Markland et al. PCT publication WO 92/15679; Breitling et al. PCT publication WO 93/01288; McCafferty et al. PCT publication WO 92/01047; Garrard et al. PCT publication WO 92/09690; Ladner et al. PCT publication WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum Antibod Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *supra*; Hawkins et al. (1992) *J Mol Biol* 226:889-896; Clackson et al. (1991) *Nature* 352:624-628; Gram et al. (1992) *PNAS* 89:3576-3580; Garrard et al. (1991) *Bio/Technology* 9:1373-1377; Hoogenboom et al. (1991) *Nuc Acid Res* 19:4133-4137; and Barbas et al. (1991) *PNAS* 88:7978-7982. Once displayed on the surface of a display package (e.g., filamentous phage), the antibody library is screened to identify and isolate packages that express an antibody that binds a component of the VEGF signaling pathway described herein. In a preferred embodiment, the primary screening of the library involves panning with an immobilized component of the VEGF signaling pathway described herein and display packages expressing antibodies that bind immobilized a component of the VEGF signaling pathway described herein are selected.

Antisense Nucleic Acid Sequences

Nucleic acid molecules which are antisense to a nucleotide encoding a component of the VEGF signaling pathway described herein, e.g., VEGF, VEGFR (e.g., flt1, flt4, KDR, neuropilin), PI3 Kinase, AKT, can be used as an agent which inhibits expression of the component. An "antisense" nucleic acid includes a nucleotide sequence which is complementary to a "sense" nucleic acid encoding the component, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can form hydrogen bonds with a sense nucleic acid. The antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof. For example, an antisense nucleic acid molecule which antisense to the "coding region" of the coding strand of a nucleotide sequence encoding the component can be used.

The coding strand sequences encoding components of the VEGF signaling pathway described herein are known. Given the coding strand sequences encoding these components, antisense nucleic acids can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest).

Administration

An agent which modulates the level of expression of a component of the VEGF signaling pathway described herein can be administered to a subject by standard methods. For example, the agent can be administered by any of a number of different routes including intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), and transmucosal. In one embodiment, the VEGF signaling pathway modulating agent can be administered topically.

The agent which modulates protein levels, e.g., nucleic acid molecules, polypeptides, fragments or analogs, modulators, and antibodies (also referred to herein as "active compounds") can be incorporated into pharmaceutical compositions suitable for administration to a subject, e.g., a human. Such compositions typically include the nucleic acid molecule, polypeptide, modulator, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances are known. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the invention. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition can be formulated to be compatible with its intended route of administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be

fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a VEGF polypeptide or anti-VEGF antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a

disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

The nucleic acid molecules described herein can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al., *PNAS* 91:3054-3057, 1994). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can include a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

The agent which modulates the activity of a component of the VEGF signaling pathway described herein can be administered by locally administration, e.g., topical administration. The agent can be applied once or it can be administered continuously, e.g., the agent is administered with sufficient frequency such that the affect on the VEGF protein level is maintained for a selected period, e.g., 5, 10, 20, 30, 50, 90, 180, 365 days or more. The administration of an agent which modulates, e.g., increases or inhibits, the level of a component of the VEGF signaling pathway described herein, e.g., a VEGF polypeptide or an anti-VEGF antibody, can also be repeated.

Transition Metals

Transition metal ions have been shown to enhance expression of the VEGF gene thereby increasing VEGF protein levels. See U.S. Patent No.: 5,480,975. Thus, in one aspect, a transition metal ion can be used to increase CTGF, thereby increasing fibrosis or angiogenesis, by increasing expression of VEGF.

The transition metals are the group consisting of the fourth, fifth and sixth levels of the periodic table and which fill the d orbital. They include such elements as Ni, Co, Mn, Zn, V, Cr, Fe, Cu, Mo, etc. The preferred candidate metal ions for use are manganese, cobalt and nickel.

Selection of other appropriate metal ions involves determining whether, and at what level, the ion will induce VEGF expression. Particularly for systemic applications, selection also involves a review of toxicity. Suitable techniques for those determinations are provided below in U.S. Patent No.: 5,480,795. Preferred ions are those with a substantial range between VEGF induction and toxicity.

The transition metal can be administered internally (systemic or local administration) in the form of a salt or free ion in a biologically compatible tablet or capsule, gel, or liquid, or it can be administered externally in the form of a biologically compatible powder, salve, liquid, or transdermal patch. Any physiologically acceptable anion such as chloride, sulfate, etc., can be included in the composition.

Appropriate release rates and dosages can be determined in order to affect the targeted tissue without substantial systemic effect. For example, these parameters can be determined as described in U.S. Patent No.: 5,480,795.

Gene Therapy

The gene constructs of the invention can also be used as a part of a gene therapy protocol to deliver nucleic acids encoding either an agonistic or antagonistic form of a component of the VEGF signaling pathway described herein. The invention features expression vectors for in vivo transfection and expression of a component of the VEGF signaling pathway described herein in particular cell types so as to reconstitute the function of, or alternatively, antagonize the function of the component in a cell in which that polypeptide is misexpressed. Expression constructs of such components may be administered in any biologically effective carrier, e.g. any formulation or composition capable of effectively delivering the component gene to cells in vivo. Approaches include insertion of the subject gene in viral vectors including recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1, or recombinant bacterial or eukaryotic plasmids. Viral vectors transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (lipofectin) or derivatized (e.g. antibody conjugated), polylysine conjugates, gramicidin S, artificial viral envelopes or other such intracellular carriers, as well as direct injection of the gene construct or CaPO₄ precipitation carried out in vivo.

A preferred approach for in vivo introduction of nucleic acid into a cell is by use of a viral vector containing nucleic acid, e.g. a cDNA, encoding a component of the VEGF signaling pathway described herein. Infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid. Additionally, molecules encoded within the viral vector, e.g., by a cDNA contained in the viral vector, are expressed efficiently in cells which have taken up viral vector nucleic acid.

Retrovirus vectors and adeno-associated virus vectors can be used as a recombinant gene delivery system for the transfer of exogenous genes in vivo, particularly into humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host. The development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased

the utility of retroviruses for gene therapy, and defective retroviruses are characterized for use in gene transfer for gene therapy purposes (for a review see Miller, A.D. (1990) *Blood* 76:271). A replication defective retrovirus can be packaged into virions which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in *Current Protocols in Molecular Biology*, Ausubel, F.M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are known to those skilled in the art. Examples of suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include *Crip, *Cre, *2 and *Am. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, in vitro and/or in vivo (see for example Eglitis, et al. (1985) *Science* 230:1395-1398; Danos and Mulligan (1988) *Proc. Natl. Acad. Sci. USA* 85:6460-6464; Wilson et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:3014-3018; Armentano et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6141-6145; Huber et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8039-8043; Ferry et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8377-8381; Chowdhury et al. (1991) *Science* 254:1802-1805; van Beusechem et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:7640-7644; Kay et al. (1992) *Human Gene Therapy* 3:641-647; Dai et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:10892-10895; Hwu et al. (1993) *J. Immunol.* 150:4104-4115; U.S. Patent No. 4,868,116; U.S. Patent No. 4,980,286; PCT Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573).

Another viral gene delivery system useful in the present invention utilizes adenovirus-derived vectors. The genome of an adenovirus can be manipulated such that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See, for example, Berkner et al. (1988) *BioTechniques* 6:616; Rosenfeld et al. (1991) *Science* 252:431-434; and Rosenfeld et al. (1992) *Cell* 68:143-155. Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are known to those skilled in the art. Recombinant adenoviruses can be advantageous in certain circumstances in that they are not capable of infecting nondividing cells and can be used to infect a wide variety of cell types, including epithelial cells (Rosenfeld et al. (1992) cited supra). Furthermore, the virus particle is relatively

stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity. Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis *in situ* where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA). Moreover, the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner et al. cited *supra*; Haj-Ahmand and Graham (1986) *J. Virol.* 57:267).

Yet another viral vector system useful for delivery of the subject gene is the adeno-associated virus (AAV). Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review see Muzyczka et al. (1992) *Curr. Topics in Micro. and Immunol.* 158:97-129). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (see for example Flotte et al. (1992) *Am. J. Respir. Cell. Mol. Biol.* 7:349-356; Samulski et al. (1989) *J. Virol.* 63:3822-3828; and McLaughlin et al. (1989) *J. Virol.* 62:1963-1973). Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb. An AAV vector such as that described in Tratschin et al. (1985) *Mol. Cell. Biol.* 5:3251-3260 can be used to introduce DNA into cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6466-6470; Tratschin et al. (1985) *Mol. Cell. Biol.* 4:2072-2081; Wondisford et al. (1988) *Mol. Endocrinol.* 2:32-39; Tratschin et al. (1984) *J. Virol.* 51:611-619; and Flotte et al. (1993) *J. Biol. Chem.* 268:3781-3790).

In addition to viral transfer methods, such as those illustrated above, non-viral methods can also be employed to cause expression of a component of the VEGF signaling pathway described herein in the tissue of an animal. Most nonviral methods of gene transfer rely on normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules. In preferred embodiments, non-viral gene delivery systems of the present invention rely on endocytic pathways for the uptake of the subject gene by the targeted cell. Exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral envelopes. Other embodiments include plasmid injection systems

such as are described in Meuli et al. (2001) *J Invest Dermatol.* 116(1):131-135; Cohen et al. (2000) *Gene Ther* 7(22):1896-905; or Tam et al. (2000) *Gene Ther* 7(21):1867-74.

In a representative embodiment, a gene encoding a component of the VEGF signaling pathway described herein can be entrapped in liposomes bearing positive charges on their surface (e.g., lipofectins) and (optionally) which are tagged with antibodies against cell surface antigens of the target tissue (Mizuno et al. (1992) *No Shinkei Geka* 20:547-551; PCT publication WO91/06309; Japanese patent application 1047381; and European patent publication EP-A-43075).

In clinical settings, the gene delivery systems for the therapeutic gene can be introduced into a patient by any of a number of methods, each of which is familiar in the art. For instance, a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g. by intravenous injection, and specific transduction of the protein in the target cells occurs predominantly from specificity of transfection provided by the gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof. In other embodiments, initial delivery of the recombinant gene is more limited with introduction into the animal being quite localized. For example, the gene delivery vehicle can be introduced by catheter (see U.S. Patent 5,328,470) or by stereotactic injection (e.g. Chen et al. (1994) *PNAS* 91: 3054-3057).

The pharmaceutical preparation of the gene therapy construct can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery system can be produced in tact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can comprise one or more cells which produce the gene delivery system.

Cell Therapy

A component of the VEGF signaling pathway described herein can also be increased in a subject by introducing into a cell, e.g., an endothelial cell, fibroblast or a keratinocyte, a nucleotide sequence that modulates the production of the component, e.g., a nucleotide sequence encoding a component polypeptide or functional fragment or analog thereof, a promoter sequence, e.g., a promoter sequence from a VEGF gene or from another gene; an

enhancer sequence, e.g., 5' untranslated region (UTR), e.g., a 5' UTR from a VEGF gene or from another gene, a 3' UTR, e.g., a 3' UTR from a VEGF gene or from another gene; a polyadenylation site; an insulator sequence; or another sequence that modulates the expression of VEGF. The cell can then be introduced into the subject.

Primary and secondary cells to be genetically engineered can be obtained from a variety of tissues and include cell types which can be maintained propagated in culture. For example, primary and secondary cells include fibroblasts, keratinocytes, epithelial cells (e.g., mammary epithelial cells, intestinal epithelial cells), endothelial cells, glial cells, neural cells, formed elements of the blood (e.g., lymphocytes, bone marrow cells), muscle cells (myoblasts) and precursors of these somatic cell types. Primary cells are preferably obtained from the individual to whom the genetically engineered primary or secondary cells are administered. However, primary cells may be obtained for a donor (other than the recipient).

The term "primary cell" includes cells present in a suspension of cells isolated from a vertebrate tissue source (prior to their being plated i.e., attached to a tissue culture substrate such as a dish or flask), cells present in an explant derived from tissue, both of the previous types of cells plated for the first time, and cell suspensions derived from these plated cells. The term "secondary cell" or "cell strain" refers to cells at all subsequent steps in culturing. Secondary cells are cell strains which consist of secondary cells which have been passaged one or more times.

Primary or secondary cells of vertebrate, particularly mammalian, origin can be transfected with an exogenous nucleic acid sequence which includes a nucleic acid sequence encoding a signal peptide, and/or a heterologous nucleic acid sequence, e.g., encoding a component of the VEGF signaling pathway described herein or an agonist or antagonist thereof, and produce the encoded product stably and reproducibly in vitro and in vivo, over extended periods of time. A heterologous amino acid can also be a regulatory sequence, e.g., a promoter, which causes expression, e.g., inducible expression or upregulation, of an endogenous sequence. An exogenous nucleic acid sequence can be introduced into a primary or secondary cell by homologous recombination as described, for example, in U.S. Patent No.: 5,641,670, the contents of which are incorporated herein by reference. The transfected primary or secondary cells may also include DNA encoding a selectable marker which confers a selectable phenotype upon them, facilitating their identification and isolation.

Vertebrate tissue can be obtained by standard methods such a punch biopsy or other surgical methods of obtaining a tissue source of the primary cell type of interest. For example, punch biopsy is used to obtain skin as a source of fibroblasts or keratinocytes. A mixture of primary cells is obtained from the tissue, using known methods, such as enzymatic digestion or explanting. If enzymatic digestion is used, enzymes such as collagenase, hyaluronidase, dispase, pronase, trypsin, elastase and chymotrypsin can be used.

The resulting primary cell mixture can be transfected directly or it can be cultured first, removed from the culture plate and resuspended before transfection is carried out. Primary cells or secondary cells are combined with exogenous nucleic acid sequence to, e.g., stably integrate into their genomes, and treated in order to accomplish transfection. As used herein, the term "transfection" includes a variety of techniques for introducing an exogenous nucleic acid into a cell including calcium phosphate or calcium chloride precipitation, microinjection, DEAE-dextrin-mediated transfection, lipofection or electrophoration, all of which are routine in the art.

Transfected primary or secondary cells undergo sufficient number doubling to produce either a clonal cell strain or a heterogeneous cell strain of sufficient size to provide the therapeutic protein to an individual in effective amounts. The number of required cells in a transfected clonal heterogeneous cell strain is variable and depends on a variety of factors, including but not limited to, the use of the transfected cells, the functional level of the exogenous DNA in the transfected cells, the site of implantation of the transfected cells (for example, the number of cells that can be used is limited by the anatomical site of implantation), and the age, surface area, and clinical condition of the patient.

The transfected cells, e.g., cells produced as described herein, can be introduced into an individual to whom the product is to be delivered. Various routes of administration and various sites (e.g., renal sub capsular, subcutaneous, central nervous system (including intrathecal), intravascular, intrahepatic, intrasplanchic, intraperitoneal (including intraomental), intramuscularly implantation) can be used. One implanted in individual, the transfected cells produce the product encoded by the heterologous DNA or are affected by the heterologous DNA itself. For example, an individual who suffers from fibrosis is a candidate for implantation of cells producing an antagonist of a component of the VEGF signaling pathway described herein.

An immunosuppressive agent e.g., drug, or antibody, can be administered to a subject at a dosage sufficient to achieve the desired therapeutic effect (e.g., inhibition of rejection of the

cells). Dosage ranges for immunosuppressive drugs are known in the art. See, e.g., Freed et al. (1992) N. Engl. J. Med. 327:1549; Spencer et al. (1992) N. Engl. J. Med. 327:1541; Widner et al. (1992) N. Engl. J. Med. 327:1556). Dosage values may vary according to factors such as the disease state, age, sex, and weight of the individual.

Examples

Example 1: VEGF modulates CTGF mRNA Expression

The effects of VEGF on the expression of CTGF mRNA were studied by Northern blot analysis in BREC and BRPC. 25 ng/ml VEGF increased CTGF mRNA (~2.4 kb) levels in a time-dependent manner, reaching a maximum after 6 h in BREC (3.1 ± 0.70 -fold, $p < 0.001$) and after 9 h in BRPC (2.0 ± 0.22 -fold, $p < 0.01$).

The dose response to VEGF-induced CTGF mRNA expression was studied after 6 h of VEGF stimulation. The expression of CTGF mRNA was up-regulated in a dose-dependent manner, with significant increases observed at concentrations as low as 0.25 ng/ml in both BREC and BRPC. Maximal increases were observed at VEGF concentrations of 25 ng/ml in both BREC and BRPC.

Since BREC and BRPC may express both KDR and Flt1, we examined the effects of PlGF, a Flt1-specific ligand, on the induction of CTGF gene expression in vascular cells. CTGF mRNA levels were not affected after stimulation of 25 ng/ml of PlGF in BREC. In contrast, PlGF increased CTGF mRNA after 3 h of stimulation, which peaked after 9 h in BRPC (1.9 ± 0.30 -fold, $p < 0.01$), suggesting that VEGF-induced CTGF gene expression was mediated primarily by KDR in BREC and Flt1 in BRPC.

Example 2: VEGF Induction of CTGF Protein Production

To determine if the effects of VEGF on CTGF mRNA were correlated with its protein level, CTGF protein expression was assessed by Western blot analysis using anti-human CTGF antibody. The detected size of CTGF protein was ~38 kDa in both BREC and BRPC. VEGF (25 ng/ml) increased the level of CTGF protein after 10 h in both BREC and BRPC. Comparative studies were performed on the effects of VEGF (25 ng/ml) and TGF- β 1 (10 ng/ml) on the expression of CTGF mRNA and protein. VEGF and TGF- β 1 increased CTGF protein expression by a similar amount (2.5 ± 0.4 - and 2.8 ± 0.8 -fold, respectively, in BREC). CTGF

mRNA levels were also increased a similar extent (3.0 ± 0.3 - and 3.3 ± 0.5 -fold, respectively).

Example 3: Effects of VEGF on the Half-life of CTGF mRNA

The effects of VEGF on the stability of CTGF mRNA were examined. Northern blot analyses were performed with addition of actinomycin D (5 μ g/ml) after 6 h of VEGF (25 ng/ml) stimulation. In BREC and BRPC3, the half-life of CTGF mRNA was 1.7 and 3.6 h, respectively. There was no significant difference between VEGF-treated and -untreated cells.

Example 4: Effects of Cycloheximide on CTGF mRNA Regulation

In order to examine the possibility that VEGF regulates CTGF mRNA expression through new protein synthesis of cytokines or transcription factors, cells were treated for 6 h with VEGF (25 ng/ml) and a protein synthesis inhibitor, cycloheximide (10 μ g/ml). Cycloheximide did not prevent the increase of CTGF mRNA. Addition of both VEGF and cycloheximide increased CTGF mRNA 2.4 ± 0.41 -fold in BREC and 2.5 ± 0.40 -fold in BRPC after 6 h as compared with cycloheximide alone ($p < 0.01$). These data suggest that the stimulation of CTGF mRNA expression by VEGF was not induced by increased synthesis of a regulatory protein.

Example 5: Involvement of Erk and PI3-Kinase-Akt in VEGF Signaling

Since Erk and PI3-kinase-Akt pathways have been reported to play central roles in VEGF signaling and biological actions, it was investigated whether or not VEGF can activate Erk and PI3-kinase-Akt pathways equally in BREC and BRPC. Immunoblot analysis of immunoprecipitates of KDR from BREC stimulated with VEGF or PlGF using an antibody to phosphotyrosine and PI3-kinase p85 subunit demonstrated that VEGF, but not PlGF, promoted the tyrosine phosphorylation of KDR and interactions of KDR and p85 subunit of PI3-kinase. In contrast, Immunoblot analysis of immunoprecipitates of Flt1 from BRPC stimulated with VEGF or PlGF demonstrated that both VEGF and PlGF increased the tyrosine phosphorylation of Flt1 and interactions of Flt1 and p85 subunit of PI3-kinase. These data suggest that VEGF can activate the receptor tyrosine phosphorylation and interaction with PI3-kinase p85 subunit in both KDR and Flt1.

To investigate the activation of Akt and Erk, we next performed immunoblot analysis with anti-phosphorylated Akt or anti-phosphorylated Erk antibodies using total cell lysates from BREC or BRPC stimulated with VEGF. VEGF induced phosphorylation of both Akt and Erk in BREC by 3.1- and 5.8-fold, but only induced phosphorylation of Akt in BRPC by 2.6-fold. No effect on Erk phosphorylation was observed in BRPC. These data suggest that VEGF activated both Erk and PI3-kinase-Akt pathways in BREC, but stimulated only PI3-kinase-Akt pathway in BRPC.

Since the activation of PI3-kinase by VEGF has not been reported in BRPC, we studied the effects of VEGF on PI3-kinase activity in BRPC. The addition of VEGF (25 ng/ml) increased PI3-kinase activity in a time-dependent manner by 2.1 ± 0.27 -fold ($p < 0.01$) after 5 min and by 1.6 ± 0.17 -fold ($p < 0.05$) after 10 min in BRPC.

Example 6: Effects of PKC, Erk, and PI3-Kinase Inhibition on VEGF-induced CTGF Expression

To investigate the signaling pathways involved in VEGF-induced CTGF expression, the effects of inhibition of PKC, Erk, and PI3-kinase were determined. Cells were treated with 25 ng/ml VEGF for 6 h after pretreatment with the kinase inhibitor GF 109203X, a classical and novel PKC-specific inhibitor (1 μ M); PD98059, a MAPK/Erk kinase inhibitor (20 μ M); or wortmannin, a PI3-kinase inhibitor (100 nM). Neither GF 109203X nor PD98059 had significant effects on VEGF-induced CTGF mRNA expression, but wortmannin inhibited the effects of VEGF by $88 \pm 6.5\%$ ($p < 0.01$) in BREC and $78 \pm 22\%$ ($p < 0.01$) in BRPC. To confirm further the involvement of PI3-kinase in VEGF-induced CTGF expression, recombinant adenoviruses were used encoding dominant negative K-ras (DNRas), dominant negative extracellular signal-regulated kinase (DNErk), or $\Delta p85$ of PI3-kinase. BREC were transfected with each adenoviral vector, followed by stimulation with 25 ng/ml VEGF for 6 h. Neither DNRas nor DNErk had significant effects on VEGF-induced increase in CTGF mRNA, but $\Delta p85$ of PI3-kinase completely inhibited VEGF-induced CTGF expression ($p < 0.001$).

Example 7: Role of PKC ζ and Akt/PKB in VEGF-induced CTGF Expression

Since it has been reported that atypical PKC and Akt/PKB have significant roles as signaling molecules downstream of PI3-kinase, the involvement of PKC ζ and Akt in this process were examined. BREC were infected with each adenoviral vector, followed by

stimulation with 25 ng/ml VEGF for 6 h. Neither wild type PKC ζ nor dominant negative PKC ζ (DNPKC ζ) had significant effects on VEGF-induced increase in CTGF mRNA. In contrast, infection with constitutive active Akt (CAAkt) increased CTGF mRNA expression 2.1 ± 0.21 -fold ($p < 0.01$) without VEGF and 2.5 ± 0.40 -fold with VEGF. Overexpression with adenoviral vector containing dominant negative Akt (DNAkt) inhibited VEGF-induced CTGF expression by $85 \pm 13\%$ ($p < 0.01$).

Example 8: Methods

A) **Materials**-- Endothelial cell basal medium was purchased from Clonetics (San Diego, CA). Endothelial cell growth factor was purchased from Roche Molecular Biochemicals. Dulbecco's modified Eagle's medium and fetal bovine serum were obtained from Life Technologies, Inc. VEGF, placenta growth factor (PlGF), TGF- β 1, and anti-CTGF antibody were ordered from R & D Systems (Minneapolis, MN). Anti-KDR (Flk1) and anti-Flt1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Protein A-Sepharose was purchased from Amersham Pharmacia Biotech. Anti-phospho-Erk, anti-Erk, anti-phospho-Akt, and anti-Akt were purchased from New England Biolabs (Beverly, MA). Anti-p85 and anti-phosphotyrosine were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Phosphatidylinositol (PI) was purchased from Avanti (Alabaster, AL), and PD98059, wortmannin, and GF 109203X were obtained from Calbiochem. All other materials were ordered from Fisher and Sigma.

B) **Cell Culture**-- Primary cultures of bovine retinal endothelial cells (BREC) and pericytes (BRPC) were isolated by homogenization and a series of filtration steps as described previously. BREC were subsequently cultured with endothelial cell basal medium supplemented with 10% plasma-derived horse serum, 50 mg/liter heparin, and 50 μ g/ml endothelial cell growth factor. BRPC were cultured in Dulbecco's modified Eagle's medium with 5.5 mM glucose and 20% fetal bovine serum. Cells were cultured in 5% CO₂ at 37 °C, and media were changed every 3 days. Cells were characterized for their homogeneity by immunoreactivity with anti-factor VIII antibody for BREC and with monoclonal antibody 3G5 for BRPC. Cells remained morphologically unchanged under these conditions, as confirmed by light microscopy. Only cells from passages 2 through 7 were used for the experiments.

C) *Recombinant Adenoviruses*— cDNA of constitutive active Akt (CAAkt, Gag protein fused to N-terminal of wild type Akt) was constructed as in Burgering et al. (1995) *Nature* 376, 599-602. cDNA of dominant negative Akt (DNAkt, substituted Thr-308 to Ala and Ser-473 to Ala) was constructed as described in Kitamura et al. (1998) *Mol. Cell. Biol.* 18, 3708-3717. cDNA of dominant negative K-Ras (DNK-Ras, substituted Ser-17 to Asn) was kindly provided by Dr. Takai (Osaka University). cDNA of dominant negative extracellular signal-regulated kinase (DNERK, substituted Lys-52 to Arg in ATP-binding site) was constructed as described in Her et al. (1993) *Biochem. J.* 296, 25-3. cDNA of $\Delta p85$ was kindly provided by Dr. Kasuga (Kobe University). cDNA of PKC ζ was kindly provided by Dr. Douglas Ways (Lilly). cDNA of dominant negative PKC ζ (DNPKC ζ , substituted Lys-273 to Trp in ATP-binding site) was constructed as in Uberall et al. (1999) *J. Cell Biol.* 144, 413-425.

The recombinant adenoviruses were constructed by homologous recombination between the parental virus genome and the expression cosmid cassette or shuttle vector. The adenoviruses were applied at a concentration of 1×10^8 plaque-forming units/ml, and adenoviruses with the same parental genome carrying the *lacZ* gene or enhanced green fluorescein protein gene (CLONTECH, Palo Alto, CA) were used as controls. Expression of each recombinant protein was confirmed by Western blot analysis and increased about 10-fold compared with cells infected with the control adenovirus.

D) *Immunoprecipitation*— Cells were washed three times with cold phosphate-buffered saline and solubilized in 200 μ l of lysis buffer (1% Triton X-100, 50 mmol/liter HEPES, 10 mmol/liter EDTA, 10 mmol/liter sodium pyrophosphate, 100 mmol/liter sodium fluoride, 1 mmol/liter sodium orthovanadate, 1 μ g/ml aprotinin, 1 μ g/ml leupeptin, and 2 mmol/liter phenylmethylsulfonyl fluoride). After centrifugation at 12,000 rpm for 10 min, 1.0 mg of protein was subjected to immunoprecipitation. To clear the protein extract, protein A-Sepharose (20 μ l of a 50% suspension) was added to the cell lysates, after which they were incubated for 1 h, followed by centrifugation and collection of the supernatant. A specific rabbit anti-KDR or Flt1 antibody was added and rocked at 4 °C for 2 h; 20 μ l of protein A-Sepharose was then added, and the sample was rocked for another 2 h at 4 °C. For denaturation, protein A-Sepharose antigen-antibody conjugates were separated by centrifugation, washed five times, and boiled for

3 min in Laemmli sample buffer.

E) Western Blot Analysis-- Immunoprecipitated proteins or 30 µg of total cell lysates were subjected to SDS-gel electrophoresis and electrotransferred to nitrocellulose membrane (Bio-Rad). The membrane was soaked in blocking buffer (phosphate-buffered saline containing 0.1% Tween 20 and 5% bovine serum albumin) for 1 h at room temperature and incubated with primary antibody overnight at 4 °C followed by incubation with horseradish peroxidase-conjugated secondary antibody (Amersham Pharmacia Biotech). Visualization was performed using the enhanced chemiluminescence detection system (ECL, Amersham Pharmacia Biotech) per the manufacturer's instructions.

F) PI3-Kinase Assay-- PI3-kinase activities were measured by the *in vitro* phosphorylation of PI as in Xia et al. (1996) J. Clin. Invest. 98, 2018-2026. Cells were lysed in ice-cold lysis buffer containing 50 mM HEPES, pH 7.5, 137 mM NaCl, 1 mM MgCl₂, 1 mM CaCl₂, 2 mM Na₃VO₄, 10 mM NaF, 2 mM EDTA, 1% Nonidet P-40, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, 5 µg/ml leupeptin, and 1 µg/ml pepstatin. Insoluble material was removed by centrifugation at 15,000 × g for 10 min at 4 °C. PI3-kinase was immunoprecipitated from aliquots of the supernatant with antiphosphotyrosine antibodies. After successive washings, the pellets were resuspended in 50 µl of 10 mM Tris, pH 7.5, 100 mM NaCl, and 1 mM EDTA. 10 µl of 100 mM MgCl₂ and 10 µl of PI (2 µg/µl) sonicated in 10 mM Tris, pH 7.5, with 1 mM EGTA was added to each pellet. The PI3-kinase reaction was initiated by the addition of 5 µl of 0.5 mM ATP containing 30 µCi of [γ -³²P]ATP. After 10 min at room temperature with constant shaking, the reaction was stopped by the addition of 20 µl of 8 N HCl and 160 µl of chloroform/methanol (1:1). The samples were centrifuged, and the organic phase was removed and applied to silica gel TLC plates developing in CHCl₃/CH₃OH/H₂O/NH₄OH (60:47:11:2). The radioactivity in spots was quantified by PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

G) Amplification of Human CTGF cDNA Using Reverse Transcriptase-Polymerase Chain Reaction (PCR)-- cDNA templates for PCR were synthesized by reverse transcriptase (First Strand cDNA Synthesis Kit, Amersham Pharmacia Biotech) from human fibroblast

according to the method recommended by the manufacturer. A standard PCR was performed (PCR optimizer kit, Invitrogen, Carlsbad, CA) using 5'-AGGGCCTCTTCTGTGACTTCG-3' (sense primer) and 5'-TCATGCCATGTCTCCGTACATC-3' (antisense primer). The PCR products were then subcloned into a vector (pCRII, Invitrogen) and sequenced in their entirety, and comparison with the published human sequences revealed complete sequence identity. This cDNA probe was used for hybridization.

H) Northern Blot Analysis-- Total RNA was isolated using acid-guanidinium thiocyanate, and Northern blot analysis was performed. Total RNA (20 µg) was electrophoresed through 1% formaldehyde-agarose gels and then transferred to a nylon membrane. ³²P-Labeled cDNA probes were generated by use of labeling kits (Megaprime DNA labeling systems, Amersham Pharmacia Biotech). After ultraviolet cross-linking using a UV cross-linker (Stratagene, La Jolla, CA), blots were pre-hybridized, hybridized, and washed in 0.5× SSC, 5% SDS at 65 °C with 4 changes over 1 h. All signals were analyzed using a PhosphorImager, and lane loading differences were normalized.

I) Analysis of CTGF mRNA Half-life-- CTGF mRNA half-life experiments were carried out using BREC and BRPC. The cells were exposed to vehicle or VEGF (25 ng/ml) for the indicated periods prior to mRNA stability measurements. Transcription was inhibited by the addition of actinomycin D (5 µg/ml). For inhibition of protein synthesis, cells were treated with cycloheximide (10 µg/ml) for the times indicated.

J) Statistical Analysis-- Determinations were performed in triplicate, and all experiments were repeated at least three times. Results are expressed as the mean ± S.D., unless otherwise indicated. Statistical analysis employed Student's *t* test or analysis of variance to compare quantitative data populations with normal distributions and equal variance. Data were analyzed using the Mann-Whitney rank sum test or the Kruskal-Wallis test for populations with non-normal distributions or unequal variance. A *p* value of <0.05 was considered statistically significant.

All patents and references cited herein are hereby incorporated by reference in their

WO 02/07747

PCT/US01/22347

entirety.

We claim:

1. A method of decreasing fibrosis in a tissue of a subject, comprising:
identifying a subject in need of decreased fibrosis; and
administering to the subject an agent that inhibits a component of the VEGF signal transduction pathway, wherein the agent decreases a connective tissue growth factor (CTGF) activity in the tissue of the subject.
2. The method of claim 1, wherein the agent decreases the level or activity of VEGF or a VEGF receptor (VEGFR).
3. The method of claim 2, wherein the VEGFR is KDR, Flt1, Flt4 or neuropilin.
4. The method of claim 2, wherein the agent is selected from the group of: a VEGF binding or VEGF receptor (VEGFR) binding protein that inhibits VEGF binding to VEGFR; an antibody to VEGF or VEGFR that inhibits VEGF or VEGFR activity; a mutated VEGF or VEGFR or fragment thereof that inhibits VEGF signaling; a VEGF or VEGFR nucleic acid molecule that inhibits expression of VEGF or VEGFR; and a small molecule that inhibits transcription or activity of VEGF or VEGFR.
5. The method of claim 1, wherein the agent decreases the level or activity of AKT.
6. The method of claim 5, wherein the agent is selected from the group of: an AKT binding protein that inhibits AKT activity; an antibody to AKT that inhibits AKT activity; a mutated AKT or fragment thereof that inhibits AKT activity; an AKT nucleic acid molecule that inhibits expression of AKT; and a small molecule that inhibits transcription or activity of AKT.
7. The method of claim 1, wherein the agent decreases the level or activity of PI3 kinase.
8. The method of claim 7, wherein the agent is selected from the group of: a PI3 kinase binding protein that inhibits PI3 kinase activity; an antibody to PI3 kinase that inhibits PI3 kinase

activity; a mutated PI3 kinase or fragment thereof that inhibits PI3 kinase activity; a PI3 kinase nucleic acid molecule that inhibits expression of PI3 kinase; and a small molecule that inhibits transcription or activity of PI3 kinase.

9. The method of claim 7, wherein the agent is LY294002.
10. The method of claim 7, wherein the agent is wortmannin.
11. The method of claim 1, wherein the subject has a fibrosis related disorder.
12. The method of claim 1, wherein the tissue is skin tissue, lung tissue, cardiac tissue, kidney tissue, liver tissue, or retinal tissue.
13. A method of decreasing angiogenesis in a tissue of a subject, comprising:
 - identifying a subject in need of decreased angiogenesis; and
 - administering to the subject an agent that inhibits a component of the VEGF signal transduction pathway, wherein the agent decreases a connective tissue growth factor (CTGF) activity in the tissue of the subject.
14. The method of claim 13, wherein the tissue is skin tissue, lung tissue, cardiac tissue, kidney tissue, liver tissue, retinal tissue, or cancerous or tumor tissue.
15. The method of claim 13, wherein the agent is selected from the group of:
 - a) an agent that inhibits VEGF activity;
 - b) an agent that inhibits VEGFR signaling;
 - c) an agent that inhibits PI3 kinase activity;
 - d) an agent that inhibits a VEGFR interaction with p85 subunit of PI3-kinase;
 - e) an agent that inhibits AKT activity; and
 - f) an agent that inhibits ERK activity.

16. The method of claim 15, wherein the VEGFR is KDR or Flt1.
17. A method of increasing fibrosis in a subject, comprising:
 - identifying a subject in need of increased fibrosis; and
 - administering to the subject an agent that induces a component of the VEGF signal transduction pathway, wherein the agent increases a connective tissue growth factor (CTGF) activity in the tissue of the subject.
18. The method of claim 17, wherein the agent is selected from the group of:
 - a) an agent that decreases a PKC activity;
 - b) an agent that increases VEGF activity;
 - c) an agent that increases VEGFR signaling;
 - d) an agent that increases VEGFR interaction with p85 subunit of PI3-kinase;
 - e) an agent that increases PI3 kinase activity; and
 - f) an agent that increases AKT activity.
19. The method of claim 17, wherein the agent is VEGF or placental growth factor (PlGF)
20. The method of claim 17, wherein the agent is a transition metal ion.
21. The method of claim 18, wherein the VEGFR is KDR or Flt1.
22. A method of screening for a compound that decreases fibrosis or angiogenesis, comprising:
 - providing a cell, tissue, or subject;
 - contacting the cell, tissue, or subject with a test compound; and
 - determining whether the test compound inhibits a component of the VEGF signaling pathway.
23. The method of claim 22, further comprising contacting the cell, tissue, or subject with VEGF.

24. The method of claim 22, further comprising assaying the cell, tissue or subject for a CTGF activity.
25. The method of claim 22, wherein the cell is an endothelial cell
26. The method of claim 22, wherein the cell is a bovine retinal endothelial cell (BREC) or bovine retinal pericyte (BRPC).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

(51) International Patent Classification⁷: **A61K 45/06**

(21) International Application Number: PCT/EP01/06976

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: **SCHERING AKTIENGESELLSCHAFT**
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimerswalder Steig 26, 13503 Berlin (DE). **HABEREY, Martin** [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIERAUCH, Karl-Heinz** [DE/DE]; Hochwildpfad 45, 14169 Berlin (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/97850 A2

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. Nature 376, 62-66, 1995), whereas Flt1
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during
10 early development of the cardiovascular system (Dumont et al., Science 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., Science 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., Proc. Natl. Acad. Sci. USA 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., Nature 376, 70-74, 1995; Rodewald & Sato, Oncogene 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and
25 lacking periendothelial support cells (Sato et al., Nature 376, 70-74, 1995; Dumont et al., Genes Dev. 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., Science 277, 55-60, 1997; Suri et al., cell 87, 1171-1180). Conversely, increased vascularization was
30 observed upon transgenic overexpression of Ang1 (Suri et al., Science 282, 468-471, 1998; Thurston et al., Science 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., Science 277, 55-60, 1997; Goede et al. Lab.

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendotherial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4
15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high
20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2
25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

Interference with Tie2 receptor function by means of Angiopoietin-neutralizing
30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 5 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. 10 Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 15 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

20 However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon 25 combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby 30 sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or
5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor
15 systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhUMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.


Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/
 antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59,
 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell
 targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-
 5 8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998),
 Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example
 molecules of general formula I

15



20

in which

r has the meaning of 0 to 2,


n has the meaning of 0 to 2;

25

R_3 und R_4 a) each independently from each other have the meaning
 of lower alkyl,

9

b) together form a bridge of general partial formula II,




5

m

wherein the binding is via the two terminal C- atoms, and has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

10



15

wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

G

20

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

A, B, D, E and T

25

independently from each other have the meaning of N or CH , with the provisio that not more than three of these Substituents have the meaning of N,

- Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or lower alkyl,
- X has the meaning of imino, oxa or thia;
- 5 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
- Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated
- 10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
- 15 more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one or more N-atoms carry an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.

These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.


25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis, respectively, which results in a prevention of tumor growth and tumor spread, are for example

anthranil acid derivatives of general formula IV

30

11



IV

in which

A

has the meaning of group $=NR^2$,

5


W

has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$, $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the group


10



15

or A, Z and R^1 together form the group

20



m, n and o

q

 $R_a, R_b, R_c, R_d, R_e, R_f$

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning

of hydrogen, C_{1-4} alkyl or the group $=NR^{10}$, and/or R_a and/ or R_b together with R_c and or R_d or R_e together with R_e and/ or R_f form a bound, or upto two of the groups R_a-R_f form a bridge witheach up to 3 C-atoms with R^1 or R^2 ,has the meaning of group $=NR^9$ or $=N-$,has the meaning of group $-(CH_2)_p$,

has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally

substituted with one or more of halogene, C_{1-6} -alkyl, or C_{1-6} -alkyl or C_{1-6} -alkoxy, which is

optionally substituted by one or more of halogen,

or is unsubstituted or substituted aryl or

heteroaryl,

has the meaning of hydrogen or C_{1-6} -alkyl, orform a bridge with up to 3 ring atoms with R_a-R_f together with Z or R_1 ,

has the meaning of monocyclic or bicyclic aryl or

heteroaryl which is unsubstituted or optionally


substituted with one or more of für halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy,

independently from each other have the meaning

of hydrogen, halogen or C_{1-6} -alkoxy, C_{1-6} -alkyl or

13


C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group



- 5 R⁸, R⁹ and R¹⁰ independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.


10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V





- 15 in which
R¹ has the meaning of group


20




14



in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,




in which R^8 is -CH₃, fluoro,
chloro or -CF₃

in which R^4 is fluoro,
chloro, bromo, -CF₃,
-N=C, -CH₃, -OCF₃ or
-CH₂OH

in which R^6 is
-CH₃ or chloro

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their
isomers and salts can be used as compound I or II in the inventive pharmaceutical
composition.

These compounds have the same properties as already mentioned above under
compound IV and can be used for the treatment of angiogeneous diseases.
Compositions comprise compounds of general formulars I, IV and V, alone or in
combination.

The above mentioned compounds are also claimed matter within the inventive
combinations.

20

A further example for ligand binding inhibitors are peptides and DNA sequences
coding for such peptides, which are used for the treatment of angiogeneous
diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59
of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of
main interest.

25

Claimed matter of the instant invention are therefor pharmaceutical compositions

- 5 a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,
- 10 b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,
- 15 c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,
- 20 d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,
- 25 e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,
- 30 f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,
- g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas. For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg.

The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with
- 5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
- 10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15 The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.
- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
- 25 tyrosine kinases Tie1 and Tie2.

- Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of
- 30 the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected
15 A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,
20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the
- 15 tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in
 5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of
 10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its
 15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000
 20 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing

10 recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons

15 when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

20

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm³, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in *E. coli* as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.
 15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm³, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)- phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a

10 reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days.

Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

15 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of a specific tyrosine kinase inhibitor and with the
 5 Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of
 15 VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of
 20 targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

25

Fig. 4 shows the superior effect on tumor growth inhibition of combination of
 targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex
 via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor
 system by means of the VEGF receptor tyrosine kinase inhibitor (4-
 30 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate
 over separate modes of intervention (treatment modes of groups 1-4 are given in
 Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
5 receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
- 10 2. Pharmaceutical compositions comprising one or several agents as compound I
which are targeted to the endothelium via of one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I
which modulates the biological function of one or several of the VEGF/VEGF
receptor systems or of one or several of the Angiopoietin/ Tie receptor systems
and comprising one or several agents as compound II which are targeted to
the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
are targeted to the endothelium via one or several of the Angiopoietin/Tie
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I
which are targeted to the endothelium via one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie
receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound
I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,
b) compounds which inhibit ligand binding to receptors,
c) compounds which inhibit activation of intracellular signal pathways of the receptors,
d) compounds which inhibit or activate expression of a ligand or of a
25 receptor of the VEGF or Tie receptor system,
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor
30 systems,
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.


20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a

14. Pharmaceutical compositions according to claims 1-11 which comprise as
25 compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as
30 compound I and/ or II at least one small molecule of general formula I

41



in which

5

r

has the meaning of 0 to 2,

n


has the meaning of 0 to 2;

R₃ und R₄

a) each independently from each other have the meaning of lower alkyl,

10

b) together form a bridge of general partial formula II,



15


wherein the binding is via the two terminal C- atoms,
and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20



has wherein one or two of the ring members T_1, T_2, T_3, T_4 the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

5 G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

R_1 and R_2 independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

20 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and


Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl,

25
30 whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

or double bonds; or an N-oxide of said compound,
 wherein one or more N-atoms carry an oxygen atom,
 or a salt thereof,

and/or a compound of general formula IV

5



in which

A

has the meaning of group $=NR^2$,

10


W

has the meaning of oxygen, sulfur, two hydrogen atoms
 or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$,
 $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the
 group


15



or A, Z and R^1 together form the group

20

44




5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/ or R _a and/ or R _b together with R _c and or R _d or R _e together with R _e and/ or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
10	X	has the meaning of group =NR ⁹ or =N-,
	Y	has the meaning of group -(CH ₂) _p ,
	p	has the meaning of integer 1-4,
15	R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
25	R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

R^4, R^5, R^6 and R^7

substituted with one or more of für halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy,


independently from each other have the meaning of hydrogen, halogene or C_{1-6} -alkoxy, C_{1-6} -alkyl or C_{1-6} -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R^5 and R^6 together form the group



R^8, R^9 and R^{10}

independently from each other have the meaning of hydrogen or C_{1-6} -alkyl, as well as their isomers and salts,


and/ or a compound of general formula V



V,


in which

R^1 has the meaning of group




in which R⁵ is chloro, bromo or the group -OCH₃,

5



in which R⁷ is -CH₃ or chloro,



in which R^8 is -CH₃, fluoro, chloro or -CF₃


in which R^4 is fluoro, chloro, bromo, -CF₃, -N=C, -CH₃, -OCF₃ or -CH₂OH

in which R^6 is -CH₃ or chloro

5

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts.

15

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

20

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

5 19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

10 20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

25




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10 <120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEPMLXX00-P

15 <140>
<141>

<160> 59

20 <210> 1
<211> 1835
<212> DNA
<213> Human

25 <400> 1

ttttacagtt ttccttttct tcagagttaa ttttgaattt tcatttttgg ataaccaagc 60
agctctttaa gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt ttttttaaatt tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccatat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
30 tatacaaaaca gccaaaaaac cataatggtg ccacagggat ggagcaggga agggcatctc 300
taacgtgtcc tctagtctat ctctgctaaa cagaaccacac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttaa 420
aagcaaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaacca acaacaacaa aaagcggagg actgtctgtt gtcactgtca aaaaggcact 540
35 ttgagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaggc ttggatgtta agagaggaca ctacagcggtt cctgaaggga gacgctgaga 660
tggaccgtcg agaagcggaa cagatgaaca caaagggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaac ccaaaacgca acctaacca agcaaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
40 gagacgtac gtgccaacct aagtctctaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgtaa gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcgggatac 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc agggggcgaca 1080
tccgccaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
45 gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac gggtagcgcg ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcaggtgggt ctgcgatagc tcatttaatg ttaaacgcca tcaggggcct ctctctccgt 1320
ttctgccagg ggttttctt gtcttctcct tggcgagctc gtgggcagat ctctctgtgt 1380
gggggctggc tgctggctcc gagggggcat ccgcagtcct tctggtcgtc tcctcctgca 1440
50 ggtctgggcag ctggccacca ctctccgac tcgacccctc caacaagcat cgaggggcac 1500
tgtcctcggg ggtacagacc gtgtccccc attcgtctacc actctgttcc acgtcatcca 1560
ggtacacgag ctgcgtgtag gccgtgctgt ctggggctcg aggtcttttc tgctgggtgt 1620
cttgagcggg cgggtagtgc tgctgcagag acaaagcatc tccccttccc ttccgggctg 1680
attttgttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
55 cagctccttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaag 1800
gagacgaacc acgcccgggg gtgcggaagc ggcct

60 <210> 2
<211> 581
<212> DNA
<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct ctttaagacc ctggggcctg tgctaccag 60
acactaaca cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
tcaacttact tcctgtggcc cattagggaa gtgggtgacct cgggagctat ttgcctgttg 180
agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
tgcccggtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
aaatgtcaag ctttgactga aaactcccg tttccagtc actggagtgt gtgcgtatga 480
aagaaaatct ttagcaatta gatgggagag aagggaaata gtacttgaaa tgtaggccct 540
cacctcccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3
<211> 516
<212> DNA
<213> Human

<400> 3

25 tagagatggt ggttgatgac ccccgggac tggagcagat gaatgaagag tctctggaag 60
tcagcccaga catgtgcac tacatcacag aggacatgct catgtcgcg aacctgaatg 120
gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240
agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
tcctgcgcat tgcaggtctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360
atgaactgga tgaggaaggc ctctattgca acagttgctt ggccagcag tgcataca 420
30 tccaagatgc ttttccagtc aaagaacca gcaataactt ttctctggat ctactcatg 480
atgaagttcc agagtttgtt gtgtaaagtc cgtctg

<210> 4
<211> 1099
<212> DNA
35 <213> Human

<400> 4

40 cccacaacac aggggcccctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60
cctgtcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180
gggtgctgctc ttggccttgc cgtgccctca tccccggct gaggcagcga cacagcaggt 240
gcaccaactc cagcaggtta agcaccagg agatgagttc aaccaccaac atgaagatga 300
45 tgaagatggt ctctccgtg gggcgagaga caaagcagtc cagcaggtag gggcagggtg 360
ctcgtgga cacaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420
ggaagcctgc ctctagcaca ctcttgaga gcacactggc gacatagggt cccatcagt 480
ctccgcggat gcgcaggcga ccactctctg ccaccgagat cttggccatc tgacgtcta 540
cgcccgccag cgcccgctcc acctgtgggt ccttggccgg cagtgcctgc agctccccct 600
ccttctgccc cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660
50 ggggtgggtgt gctgacgaag aggaactgca gcacccagta gcggtgtgg gagatgggga 720
aggcctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
actgctcgtc accccacact gactcgccgg ccaggccag gatgaggatg cggaagatga 840
agagcaccgt cagccagatc ttacccacca cggctcagtg ctcttgacc tggccagca 900
acttctccac gaagccccag taccatgg ctcccgggc tccgtcggca aggagacaga 960
55 gcacgtcagt gtgtcagcat ggcatcctc tcgttcgccc agcaacaagc ctgcagggag 1020
gtctgccacg cccgttctac cgctgcctg cggggcgcc caggtggagg tggggacgat 1080
ggccggagtg acgcccgcg

<210> 5
60 <211> 1015
<212> DNA
<213> Human

<400> 5

65 gaggataggg agcctggggg caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

5 aaaaagtgtct ttttgaataat gttgaggttg aaatgatggg aaccaacatt ctttggattt 120
 agtggggagc ataataagcaa acacccccctt ggttcgcaca tgtacaggaa tgggacccag 180
 ttggggcaca gccatggact tccccgccct ggaatgtgtg gtgcaaagtg gggccagggc 240
 ccagacccaa gaggagaggg tgggtccgcag acaccccggt atgtcagcat cccccgacct 300
 10 gccttctggc ggcacctccc ggggtgtgtg ttgagtcagc aggcattggg tgagagcctg 360
 gtatatgtct ggaacagggg gcaggggcca agcggttcctc cttcagcctt gacttggggc 420
 atgcaccccc tctcccccaa acacaaacaa gcacttctcc agtatgggtg caggacaggt 480
 gtccttctcag tctctgtggt atgacctcaa gtccacttg ggcctgcag cccagcctgt 540
 gttgtaacct ctgcgtcctc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600
 15 atcatcattg ttgctttatc acttctaaga cattttgtac ggcacggaca agttaaacag 660
 aatgtgcttc cctccctggg gtctcacacg ctcccacgag aatgccacag gggccgtgca 720
 ctgggcaggc ttctctgtag aaccccaggg gcttcggccc agaccacagc gtcttgccct 780
 gagcctagag cagggagtc cgaacttctg cattcacaga ccacctccac aattgttata 840
 accaaaggcc tctgttctg ttatttctac taaatcaaca tgctattttg ttttactca 900
 20 cttctgactt tagcctctg ctgagccgtg tatccatgca gtcattgtca cgtgctagtt 960
 acgtttttct tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa

 <210> 6
 <211> 2313
 <212> DNA
 <213> Human

 <400> 6

 25 ccagagcagg cctgggtggg agcagggagc gtgcaccgga cggcgggagc gagcaaatgg 60
 gtctggccat ggagcacgga gggctctacg ctccggcggg gggcagctct cggggctgct 120
 ggtattacct gcgctacttc ttctctctcg tctccctcat ccaattcctc atcatcctgg 180
 ggctcgtgct cttcatgggt tatggcaacg tgcacgtgag cacagagtcc aacctgcagg 240
 30 ccaccgagcg ccgagccgag ggcctataca gtcagctcct agggctcacg gcctcccagt 300
 ccaacttgac caaggagctc aacttcacca ccgcgcgcaa ggtatgccatc atgcagatgt 360
 ggctgaatgc tcgcgcgcag ctggaccgca tcaatgccag cttccgcag tgccaggggtg 420
 accgggtcat ctacacgaac aatcagaggt acatggctgc catcatcttg agtgagaagc 480
 aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcatgctga 540
 atcagaaggt gaagacgctg gaggtggaga tagccaagga gaagaccatt tgcactaagg 600
 35 ataaggaaag cgtgctgctg aacaaacgag tggcgaggga acagctgggtt gaatgcgtga 660
 aaacccggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaaggtgca 720
 agccctctgc ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780
 ggactccatt atcccacgca gcctggacaa cctgggttac aacctctacc atcccctggg 840
 40 ctcggaattg gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900
 ggtggaggag ctggcccggg gcctccgggc ggatategaa cgcgtggccc gcgagaactc 960
 agacctcaa cgccagaagc tggaagccca gcagggcctg cgggcccagc aggaggcgaa 1020
 acagaagggt gagaaggagg ctacagcccc ggaggccaag ctccaagctg aatgctcccg 1080
 gcagacccag ctagcgtgag aggagaaggc ggtgctgcgg aaggaaacgag acaacctggc 1140
 caaggagctg gaagagaaga agaggagggc ggagcagctc aggatggagc tggccatcag 1200
 45 aaactcagcc ctggacacct gcatcaagac caagtgcag cccgatgatg cagtgtcaag 1260
 gccctgggc cctgtcccca acccccagcc catcgaccca gctagcctgg aggagttcaa 1320
 gaggaagatc ctggagctcc agaggcccc tgcaggcatc cctgtagccc catccagtgg 1380
 ctgaggaggc tccaggcctg aggaccaagg gatggcccga ctcgcggtt tgcggaggat 1440
 gcagggatat gctcacagcg cccgacacaa cccctcccg ccgccccaa ccaccaggg 1500
 50 ccaccatcag acaactccct gcatgcaaac ccctagtacc ctctcacacc cgcaccgcg 1560
 cctcacgac cctcaccagc agcacacggc cgcggagatg acgtcacgca agcaacggcg 1620
 ctgacgtcac atatcaccgt ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680
 tatagcgatg gcgtcgtgca gatgcagcac gtgcacaca gacatgggga acttggcatg 1740
 55 acgtcacacc gagatgcagc aacgacgtca cgggccatgt cgacgtcaca catattaatg 1800
 tcacacagac gcggcgatgg catcacacag acggtgatga tgtcacacac agacacagtg 1860
 acaacacaca ccatgacaac gacacctata gatatggcac caacatcaca tgcacgcatg 1920
 ccttttcaca cacactttct acccaattct cacctagtgt cacgttcccc cgaccctggc 1980
 acacggggcca aggtaccac aggatcccat cccctcccg acagccctgg gccccagcac 2040
 60 ctcccctcct ccagcttctt ggcctccag ccacttctc acccccagtg cctggaccct 2100
 gaggtgagaa cagggaagcca ttcacctcg ctcttgagc gtgagtggtt ccaggacccc 2160
 ctggggggcc tgagccgggg gtgaggggtc cctgtgtgct ggaggggagc cactccttct 2220
 cccccaactc ccagccctgc ctgtggcccg ttgaaatgtt ggtggcactt aataaatatt 2280
 agtaaatcct taaaaaaaaa aaaaaaaaaa aaa

<212> DNA
<213> Human

<400> 7

5

10

gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgg tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa ttttctggga 300
gaacctgag ctattaataa tctatgtggc tagtgcgtat atattggtct gaatttggtc 360
tccttttgtg gtgtccagtg ggtaacatc

15

<210> 8
<211> 157
<212> DNA
<213> Human

20

<400> 8

tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagcccac tcaaactgtg aatttggtcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg

25

<210> 9
<211> 561
<212> DNA
<213> Human

30

<400> 9

35

40

aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttgttg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttccccttgc 120
tgaactgaac tattctgtta catatggttg acaaactctg gtgttatttc ttttctacct 180
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420
ttaaacctat aatgagtatt ctaaatggag aattcttaat ggatggatta tcccctgata 480
ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgcccacat ttctaggaaa a

45

<210> 10
<211> 1508
<212> DNA
<213> Human

<400> 10

50

55

60

65

cacaaacacg agagactcca cggctctgcct gagcaccgcc agcctcctag gctccagcac 60
tcgcaggtec attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtagcag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctcctccgg gcctgttgcct gatggcataa tccgggtgca acccaaactc 240
gagctcaagc caggtgagct taagccactg agcaaggaa atttgggctt gcaagcctac 300
aggtgtgagg actgtggcaa gtgcaaatgt aaggagtgc cctaccaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480
tgtgtctgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540
ggtgtcatgt cctctttttt gccttgttta tgggtttacc ttccagccaa ggggtgcctt 600
aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaagt tcccactgtc ccccttagga actttgaaaa accaactatg 720
catcattaat caggaatatt acagtaatga ggattttttt tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagtgg gatagtcttt 840
gctgtttggc gtgaaatgct ttttgtccat gtgcccgttt aactgatag cttgttagaa 900
ctcagctaatt ggagctcaaa gtatgagata cagaacttgg tgacctatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaag tttttgtttg tgaatagtac ttgcaaaact 1020

tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatTTTT 1080
 gtatatacaa taatatttgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140
 cacaaaatat tatactaata tgttgtagat tcggaagaat gtgaatcaat cagtatgttt 1200
 ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260
 5 ttcattgtata ttgtacagt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320
 attgtttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaataattta 1380
 ttttaagagg catcttacia attttgcccc ttttatgagg atgtgatagt tgctgcaa 1440
 gagggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaaaa
 10 <210> 11
 <211> 389
 <212> DNA
 <213> Human
 15 <400> 11
 gggcaggtga tcagggcaca catttcccgt ccattgagac agtagcattc ccggcaccca 60
 20 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cggtgagaca agtgcccagc 120
 aggatgggtg gccagctga agcacaggcc gctctgact tgagataag acagccgtga 180
 ctgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360
 acctcgggccc cgaccacgct ggttaccga
 25 <210> 12
 <211> 981
 <212> DNA
 <213> Human
 30 <400> 12
 tttttttttt ttggattgca aaaatttatt aaaattggag acactgtttt aatcttcttg 60
 35 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggtgagg atcacttgag 120
 ccagaaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggtcattaaa aaccctagtt 240
 taggataaca acatattaat cagggcacaaa tacaaatgtg tgatgcttgt tagtagagta 300
 acctcagaat caaaatggaa cgggttttaca gtgatatcat tatatttcat ttggcagaat 360
 40 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcaccctagt 420
 taggataaca ggtctgcctg tttgaagatg aaaaataata ccattttaa atttgcccta 480
 ctcaatttcc ttctcagta cattttaact tttaaacagc taatcactcc catctacaga 540
 ttaaggtgta tatgccacca aaaccttttg ccaccttaaa aatttccttc aaagttaa 600
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaactgtctc 660
 45 cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720
 taccaggagc agaaccatta agctggtcca ggcaagttgg actccaccat ttcaacttcc 780
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840
 agtagctatt ctcatccttc cttggggaca caactgtcca taaggtgcta tccagagcca 900
 cactgcatct gcacccagca ccatacctca caggagtcga ctcccacgag ccgcctgtat 960
 50 ataagagttc ttttgatgac g
 <210> 13
 <211> 401
 <212> DNA
 <213> Human
 55 <400> 13
 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 60 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120
 tctctccccc agagcgaccc cccgggcagg tcggggccca aggaatgacc cagcaactgc 180
 tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240
 gtgggtcatca cgattcagag aaatcaagat ctatgaccat tttaggcaaa gagagaaact 300
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaactctc 360
 65 acttcagcat atttagttgt cattaaaatt aagctgat t
 <210> 14

<211> 1002
<212> DNA
<213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
acagttgtgg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
10 tttgaaaatg ttaaatacaa gtcctattct ctttgccag ctgggttag ctagaggtag 180
ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
gaagtaaata tctggggccc atcgacccc cactaagtac tttgtcacca tgttgatct 300
taaaagtcatt ttttctactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gaggatatt 420
15 tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
tactgaaaac aatgggtgcc tatgctccaa agacatttcc ccaagataac tgccaaagag 540
tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
attaatacag ctcaaatgga gtagtaacca agcttttctg cccaggaagt acaaacatc 660
actacgaaca tgagagtaca agaggaaact ttcataatgc atttttcat tcatacattc 720
attcaataaa cattagccaa gctaattgtc caagccactg tgccaggat taacaatata 780
20 acaacaataa aagacacagt ccttcctctc aagggtgtca gtctagtagg gaagatgatt 840
attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaatcct 900
gcctatgttc tcagatatc tggttaggtc aggagtggga acccaaatc aattcttta 960
acaacacta aagggtgattc taacacaggc ggtgtgagga cc

25 <210> 15
<211> 280
<212> DNA
<213> Human

30 <400> 15

cgaggtgggc caccctgtgc tggctctgaga tttttaaatg aggattacat tatcctattt 60
ataatattcc tattctaattc tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180
35 aactgtatta tgactctcaa tatttaaaaca tttaaaaaaa tgtagtggtt tgtaagcac 240
caatcttaac tatttcacct gcccgggcgg ccgctcgagg

40 <210> 16
<211> 2041
<212> DNA
<213> Human

<400> 16

45 cccccgcag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60
atagagggtta gcatttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
50 aattttgtta ttgccttctt tagagacttt ataattctta gttgattttc aaggacttga 300
atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480
caggtacata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
gaattttaag aggtagattt ttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
55 ataaaaacaa gcactgagtg tgtctctctg aagtataagg gtctaataag aaataaaaga 660
tagatatttg ttatagctct acatttttaac agtcatagta ttagacgttt cgtgaccagt 720
gcatttttga ctctctcagg atcaaaatac gactctgcca actgtattaa atcctcctcc 780
acccctcca ccagttgggc cacagcttcc tgggtgggtc ttgtcatcaa atccattggg 840
ccgaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactctg 900
60 ttcctgtaaa tatagtttat tgtcttttct tatagcatcc ataagttctt tctgtagagg 960
tgggtctcca tttatccaga gtccactggg tgggttatta ccacttaaac cattagtact 1020
atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tcgtaatttt 1080
ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140
ttgaacttcc cttattttcc aaatcctggt caaaaactgc actgggacta tctctcccta 1200
65 gtaaatgact ctgggaggat gctaagtcca ggcctcaga ctgggtgtac atctgatatg 1260
aagagtctgt acttgtgata tttctggcat aagaatagta atgccactt tcagaggata 1320

taccagagtg aaccacaacg gaacttaata gatagggcac caattttgtg caggaagctt 1380
 catcagtcctc tgaaggcttt aatttttttag caagggtctc actaagatca gtgaagtcaa 1440
 catctacaga ccaactttct gacaatgaag agaaagaagt aattcttcta actggcaact 1500
 ccaaaccag tggccagtga tacattgtct aaaattttcc ttctcacatg atacttctga 1560
 5 tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctccgt gatttgcata 1620
 gttttctcag ctttttgcag agaggcacag ttttcacaat aatattggtt atcaccagta 1680
 agaattctctg gagcccaaaa aataattttag taagtcagtt actgaagggtg tggtttcacc 1740
 tccccggttc tgaggtacat ctttattaac aagaatcttg ttagattcgt tagggacaga 1800
 10 agtgttttca gaacagtaaa actcatttag aggactgcct atgggttttt cattcacaag 1860
 tgagtcacag atgaaggcag ctgttgttgg attataaact actggctctt ctgaaggacc 1920
 gggtagacag gcttgcatta gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980
 gacagacatg ttttccaaag aagaggaagc acaaacgcga agcgaaagat ctgtaaaggc 2040
 t
 15 <210> 17
 <211> 235
 <212> DNA
 <213> Human
 20 <400> 17
 cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagacccctc 60
 acctctacaa ataaaaaatt aaaaaattag ccagggtgtg cagcgaacaa ctgtagtctc 120
 agataactcag gagactgagc tggaaaggat cacttgagcc caagaagttc aagggttacag 180
 25 tgggccacga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta
 <210> 18
 <211> 2732
 <212> DNA
 30 <213> Human
 <400> 18
 35 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60
 tcatgttgat aactacttta tatggagctt cattggacct gttaccttca ttattctgct 120
 aaatattatc ttcttgggtga tcacattgtg caaaatggtg aagcattcaa acactttgaa 180
 accagattct agcaggttgg aaaaacttaa gtcttgggtg cttggcgctt tcgctcttct 240
 gtgtcttctt ggcctcacct ggtcctttgg gttgctttt attaatgagg agactattgt 300
 gatggcatat ctcttacta ttttaattgc tttccaggga gtgttcattt tcatctttca 360
 40 ctgtgctctc caaaagaaag tacgaaaaga atatggcaag tgcttcagac actcactatg 420
 ctgtggaggc ctcccaactg agagtcccca cagttcagtg aaggcatcaa ccaccagaac 480
 cagtctctgc tattctctg gcacacagag tcgtataaga agaattgtga atgatactgt 540
 gagaaaacaa tcagaatctt cttttatctc aggtgacatc aatagcactt caacacttaa 600
 tcaaggtggc ataaatctta atatattatt acaggactga catcacatgg tctgagagcc 660
 45 catcttcaag atttatatca tttagaggac attcactgaa caatgccagg gatacaagt 720
 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgtg cacaaggggt 780
 actataatga cagcgtgcaa gttgtggact gtggactaag tctgaatgat actgcttttg 840
 agaaaatgat catttcagaa ttagtgcaca acaacttacg gggcagcagc aagactcaca 900
 acctcgagct cacgctacca gtcaaacctg tgattggagg tagcagcagt gaagatgatg 960
 50 ctattgtggc agatgcttca tctttaatgc acagcgacaa cccagggctg gagctccatc 1020
 acaaagaact cgaggcacca cttattcctc agcggactca ctccctctg taccaacccc 1080
 agaagaaagt gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140
 aagatcacct acagtcccc aacagagact ctctttatac aagcatgccc aatcttagag 1200
 actctcccta tccggagagc agccctgaca tggaagaaga cctctctccc tccaggagga 1260
 55 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320
 agatgtgcta ccagatcagc aggggcaata gtgatggtta tataatcccc attaacaaa 1380
 aaggtgtgat tccagaagga gatgttagag aaggacaaat gcagctggtt acaagtctt 1440
 aatcatacag ctaaggaatt ccaagggcca catgcgagta ttaataaata aagacaccat 1500
 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgtggttctc 1560
 60 tgggtgaaaa aagatgactg aaccttgacg ttctgtgaat ttttataaaa catacaaaa 1620
 ctttgtatat acacagagta tactaaagtg aattatttgt tacaagaaa agagatgcca 1680
 gccaggtatt ttaagattct gctgctgttt agagaaattg tgaaacaagc aaaacaaaac 1740
 tttccagcca ttttactgca gcagtctgtg aactaaattt gtaaatatgg ctgcaccatt 1800
 tttgtagggc tgcattgtat tatatacaag acgtaggctt taaaatcctg tgggacaaat 1860
 65 ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagatat tctgcatcag 1920
 tttgcagttc actgcaaatc ttttacatta aggcaaagat tgaaaacatg ctttaaccact 1980

5 agcaatcaag ccacaggcct tatttcatat gtttcctcaa ctgtacaatg aactattctc 2040
 atgaaaaatg gctaaagaaa ttatatatttg ttctattgct agggtaaaat aaatacattt 2100
 gtgtccaact gaaatataat tgtcattaaa ataattttta agagtgaaga aaatattgtg 2160
 aaaagctctt gggtgcacat gttatgaaat gttttttctt acactttgtc atggtaagt 2220
 ctactcattt tcacttcttt tccactgtat acagtgttct gctttgacaa agttagtctt 2280
 tattacttac atttaaat 5 cttattgcca aaagaacgtg ttttatgggg agaaacaaac 2340
 tctttgaagc cagttatgtc atgccttgca caaaagtgat gaaatctaga aaagattgtg 2400
 tgtcacccct gtttattctt gaacagaggg caaagagggc actgggcact tctcacaac 2460
 tttctagtga acaaaagggt cctattcttt tttaaaaaaa taaaataaaa cataaatatt 2520
 10 actcttccat attccttctg cctatattta gtaattaatt tattttatga taaagttcta 2580
 atgaaatgta aattgtttca gcaaaattct gctttttttt catccctttg tgtaaacctg 2640
 ttaataatga gccatccact aatatccagt gtaaagttta acacggtttg acagtaata 2700
 aatgtgaatt ttttcaagtt aaaaaaaaaa aa

15 <210> 19
 <211> 276
 <212> DNA
 <213> Human

20 <400> 19

25 ctccctaagt gatttttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60
 aaccgccttt gcataatttt tatgtacaaa tctttgtata caattccgat gttccttata 120
 tattccctat atagcaaac aaaaccagga cctcccaact gcatgcctca agtccctgtg 180
 gagcactctg gcaactggat ggccctactt gctttctgac aaaatagctg gaaaggagga 240
 gggaccaatt aaatacctcg gcgcgcacca cgctgg

30 <210> 20
 <211> 2361
 <212> DNA
 <213> Human

<400> 20

35 attgtaccag ccttgatgaa cgtgggcccct gcttcgcttt tgaggggccat aagctcattg 60
 cccactgggt tagaggctac ctatcattg tctcccgtga ccggaagggt tctcccaagt 120
 cagagtttac cagcagggat tcacagagct ccgacaagca gattctaaac atctatgacc 180
 tgtgcaacaa gttcatagcc tatagcaccg tctttgagga tgtagtggat gtgcttgctg 240
 40 agtggggctc cctgtacgtg ctgacgcggg atgggcgggt ccacgcaact caggagaagg 300
 acacacagac caaactggag atgtgttata agaagaacct atttgagatg gcgattaacc 360
 ttgccaagag ccagcatctg gacagtgtg ggctggccca gattttcatg cagtatggag 420
 accatctcta cagcaagggc aaccacgatg gggctgtcca gcaatatatc cgaaccattg 480
 gaaagtggga gccatcctac gtgatccgca agtttctgga tgcccagcgc attcacaacc 540
 tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccgac cataccacc 600
 45 tgctcctcaa ctgctatacc aagctcaagg acagctcgaa gctggaggag ttcatcaaga 660
 aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaagggt ctcggcagg 720
 ctggctacta ctcccatgcc ctgtatctgg cggagaacca tgcacatcat gactggtacc 780
 tgaagatcca gctagaagac attaagaatt atcaggaagc ccttcgatac atcggcaagc 840
 tgccctttga gcaggcagag agcaacatga agcgctacgg caagatcctc atgcaccaca 900
 50 taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg cccagcctcg 960
 aaggccgcag cgtataggag gccccaggct gcagggccaa ctctgaggag ttcatcccca 1020
 tctttgccaa taaccgcga gagctgaaag ccttctctaga gcacatgagt gaagtgcagc 1080
 cagactcacc ccaggggatc tacgacacac tcttgagct gcgactgcag aactgggcc 1140
 acgagaagga tccacaggtc aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200
 55 gtggctcgct ctgacagctc tttgacaagg ccctggctct gtgccagatg cagcacttcc 1260
 aggatgggtg cctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcactacc 1320
 acatgcagca cgagcagtag cggcagggtc tcagcgtgtg tgagcgccat ggggagcagg 1380
 acccctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440
 agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgcca cctcttctag 1500
 60 tgggtgcagac cctggcccac aactccacag ccacactctc cgtcatcagg gactactctg 1560
 tccaaaaact acagaaacag agccagcaga ttgcacagga tgagctgcgg gtgcggcggt 1620
 accgagagga gaccacccgt atccgccagg agatccaaga gctcaaggcc agtcctaaga 1680
 ttttccaaaa gaccaagtgc agcatctgta acagtgcctt ggagttgcc tcagtccact 1740
 tcctgtgtgg ccactccttc caccaacact gctttgagag ttactcggaa agtgatgctg 1800
 65 actgcccac ctgcctccct gaaaaccgga aggtcatgga tatgatccgg gcccggaac 1860
 agaaacgaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920

ctgtgattgc tgactacttt ggagaggtg ttttcaacaa attgactctg ctgaccgacc 1980
 ctcccacagc cagactgacc tccagcctgg aggctgggct gcaacgcgac ctactcatgc 2040
 actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100
 agaacagaca caatgggacc tggcgggcg ttacacagaa ggctggctga catgcccagg 2160
 5 gctccactct catctaagt cacagccctc acaagactaa agcggaactt tttcttttcc 2220
 ctggccttcc ttaattttta gtcaagcttg gcaatccctt cctctttaac taggcaggtg 2280
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaaccc tcctgaagtt 2340
 ttggaaaaaa aagctggttt c

10 <210> 21
 <211> 179
 <212> DNA
 <213> Human

15 <400> 21
 aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60
 acaataactg aaaggaactg agagaaacct acaacacaca gcagttagcc cttgaacagc 120
 ttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

20 <210> 22
 <211> 905
 <212> DNA
 <213> Human

25 <400> 22
 tttttttttt ttctttaacc gtgtggtctt tatttcagtg ccagtgttac agatacaaca 60
 caaatgttcc agttagaagg aattcaaagc gaatgccaaag gtccaagcca ggctcaagaa 120
 30 ataaaaaggg aggttttgag taatagataa gatgactcca atactcactc ttccctaaggg 180
 caaagggtact ttgtatagag agtctgatct ttgaaactgg tgaactcctc ttccacccat 240
 taccatagtt caaacaggca agttatgggc ttaggagcac tttaaaattt gtggtgggaa 300
 taggggtcatt aataactatg aatatatctt ttagaagggt accattttgc actttaaagg 360
 gaatcaattt tgaatatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420
 35 gggagctgga agagccttgg aagtttctat tacaataga gcaccatata cttcatgcca 480
 aatctcaaca aaagctcttt ttaactccat ctgtccagtg tttacaata aactcgcaag 540
 gtctgaccag ttcttggtta caaacatata tgtgtgtgtc tgtgtgtata cagcaatgca 600
 cagaaaaggc taccaggagc ctaatgcctc tttcaaactg tgggggaacc agtagaaaaa 660
 ggcagggtcc cctaattgcc attattacat ttccattccg aatgccagat gttaaaagt 720
 40 cctgaagatg gtaaccacgc tagtgaggaa taaatacccc accttgcaca gtccacagag 780
 aaacaacagt agaaagaagg ggcaactctt tgctgcagag acaaagttag tgttttttcg 840
 ccatggattg cagtcctctc ctccagacca gtgcttatt tcctcagggg cccagggaaat 900
 gttga

45 <210> 23
 <211> 2134
 <212> DNA
 <213> Human

50 <400> 23
 ggtctcttct ttcccttttt tttttccaaa agtgttcttt tatttctagt aacatatatt 60
 gtataaatac tctattttat atgcacttcc acaaagcgga tataatttaa aagttttttt 120
 cattagaaat aaatgtataa aaataaatat gttattatag gcatttatta ctaactatag 180
 55 tccttcttgg aaggaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240
 tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300
 accaggatag gactgttgga ccagctgctg gagatggacc tgctaccctc cagcagcctc 360
 cccaccacaa gacaagtgat ctcaatgtcc ccaaacctgt gggaccctgt tctacacacc 420
 tcatttttgt tccggcggtt catcctcctt gtgtgattgt actgattttc atgagacaca 480
 60 agttacttct ttacatccat attcccaaag cagggttaca tggtaggaaa gaaaggaaat 540
 tggagggtact aagctcattg tgtctcctct agcttttacc agcatctaat gcttcactgc 600
 tttttttcca ttgtagactt taatgcactt gaataaatac atggagttgt ttttctctca 660
 aaatgaatta cacaaataaa gactgagatg gtccaaaaaa ggaagagga agccatttgc 720
 gttatttcac gttgctgagc ctttctctca tgttgaaaca tctgaagttt taattctcgg 780
 65 tagaaataat gtataaacat tctctgaaac catagcagcc ataaacagtg ctgggtcaaa 840
 atcctatttg tactcctttc tccccccatt gttagttagg taaagtaaaa cagggtctag 900

taaaatctca cttttctect acttttcatt tcccaacccc catgatacta agtatttgat 960
 aagtaccagg aaacaggggt tgtaatagtt ctaacttttt ttgacaattg ctttggtttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccgg ggctttatta 1080
 5 tgctatatca ctgctcagag gttaataatc ctcactaact atcctatcaa atttgcaact 1140
 ggaggtttac tctgatgatt caactccttt tctatctacc ccataatcc caccttactg 1200
 atacacctca ctgggtactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260
 gcaccagccc ttcctcactt tgccttgccc tcaaagctaa caccacttaa accacttaac 1320
 tgcattctgc cattgtgcaa aagtctatga aatgtttagg tttctttaaa ggatcacagc 1380
 10 tctcatgaga taacaccctt ccatcatggg acagacactt caagcttctt tttttgtaac 1440
 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
 ggtctgcaca aggtctggtg ctggctggct tcacttctt tgcacactcg gaagcaggt 1560
 gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680
 ccttcttctt ctttacgaag taggtgtatt taattttagg tcgaagggca ttgccacag 1740
 15 taagaacctg gatggtcaag ggctcttga gagggctaaa gctgcgaatt ctttccaatg 1800
 ccgagagga gccgctgtac ctcaagacaa cacttttga cataatgtct tgcctaaag 1860
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920
 agctgccatt gttcctggat cccctctggt tccgctggtt cacttcgatg ttggtggctc 1980
 cagttggaat tgtgatgata tcatgatata caggttttgc actagtaact gatcctgata 2040
 20 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttctttttgg 2100
 agtctatgat gcgatcaca ccagctttta caca

 <210> 24
 <211> 1626
 25 <212> DNA
 <213> Human

 <400> 24

 30 ggacaatttc tagaatctat agtagtatca gगतatattt tgcttttaaa tatattttgg 60
 ttattttgaa tacagacatt ggctccaaat tttcatcttt gcacaatagt atgacttttc 120
 actagaactt ctcaacattt gggaaacttg caaatatgag catcatatgt gttaaggctg 180
 tatcatttaa tgcctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaactg 240
 35 agttgttttt tactgatact aaatgttggc tacctgtgat tttatagtat gcacatgtca 300
 gaaaaaggca agacaaatgg cctctgttac tgaatacttc ggcaaaactta ttgggtcttc 360
 atttctgac agacaggatt tgactcaata tttgtagagc ttgctgtagaa tggattacat 420
 ggtagtgtat cactggtaga aatgggtttt agttattgac tcagaattca tctcaggatg 480
 aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atgggttttag 540
 aaagctttgt ctaaaaattt ggcttaggaa tggtaacttc attttcagt gccaaggggt 600
 40 agaaaaataa tatgtgtgtt gttatgttta tgtaacata ttattaggtta ctatctatga 660
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720
 ccatttagcc cagtgggaaa gtcttggaac tcaggttacc cttgaaggat atgctggcag 780
 ccatctcttt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840
 45 tctggaatgc attagttatg ccttgtagca ttcccagaat ttcaggggca tctgtgggtt 900
 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140
 50 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200
 cgttgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtag tgcaatcaca 1320
 atgccagatg gtgtttatgg gctattttgt taagtaagt gtaagatgct atgaagtaag 1380
 tgtgtttgtt ttcatcttat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440
 tgggtgcaata tgatgtcatt caacttttga ttgaattgaa ttttggttgt atttatatgt 1500
 55 attatacctg tcacgcttct agttgcttca accattttat aaccattttt gtacatatatt 1560
 tacttgaaaa tattttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620
 aaaaaa

 <210> 25
 60 <211> 1420
 <212> DNA
 <213> Human

 <400> 25

 65 gtccagcatt gtttctgctt ctgaaatctg tatagtacac tgggtttgtaa tcattatgtc 60

ttcattgaaa tccttgctac ttctcttcct cctcaatgaa agacacgaga gacaagagcg 120
 acacaagctt aagaaaaacg agcaaggaag agtatcttca ttattctcat tttctctgag 180
 ttggaaacaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240
 agtgggaaaa ctttaagagt ttccacatat tagttttcat ttttgagtc aagagactgc 300
 5 tccttgtagt gggagacact agtagtatat gtttgtaatg ttactttaaa attatctttt 360
 tattttataa ggcccataaa tactgggttaa actctgttaa aagtgggcct tctatcttgg 420
 atggtttcac tgccatcagc catgctgata tattagaaat ggcatcccta tctacttact 480
 ttaatgctta aaattatata taaaatgctt tatttagaaa acctacatga tacagtgggtg 540
 10 tcagccttgc catgtatcag tttcacttga aatttgagac caattaaatt tcaactgttt 600
 aggggtggaga aagaggtagt ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660
 atcctttgca tgggaggaga gttactcttg aaaggcaggc agcttaagtg gacaatgttt 720
 tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780
 tttgctctgt tttgctgaa gtttttagtat ttgttttcta ggtggacctc tgaaaaccaa 840
 15 accagtagctt ggggagggtta gatgtgtgtt tcaggcttgg agtgtatgag tggttttgct 900
 tgtattttcc tccagagatt ttgaacttta ataattgcgt gtgtgttttt ttttttttaa 960
 gtggctttgt ttttttttct caagtaaaat tgtgaacata tttcctttat aggggcaggg 1020
 catgagttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgtttc 1080
 tcgacacatt ttttttcagt aacttgaaaa ttcaaaaggg acatttggtt aggttactgt 1140
 20 acatcaatct atgcataaat ggcagcttgt ttcttgagc cactgtctaa attttgtttt 1200
 tatagaaatt ttttatactg attggttcat agatggtcag ttttgtagac agactgaaca 1260
 atacagcact ttgcaaaaaa tgagtgtagc attgttttaa cattgtgtgt taacacctgt 1320
 tctttgtaat tgggttgttg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380
 agtaataaaa gtgtccttta acttcaaaaa aaaaaaaaaa

25 <210> 26
 <211> 689
 <212> DNA
 <213> Human

30 <400> 26

aaacaaacaa aaaaaaagtt agtactgtat atgtaaatac tagcttttca atgtgctata 60
 caaacaatta tagcacatcc ttctttttac tctgtctcac ctcttttagg tgagtacttc 120
 35 cttaaataag tgctaaacat acatatacgg aacttgaaag ctttggttag ccttgcccta 180
 ggtaatcagc ctagtttaca ctgtttccag ggagttagtg aattactata aaccattagc 240
 cacttgcttc tgcaccattt atcacaccag gacagggctc ctcaacctgg gcgctactgt 300
 catttggggc cagggtgattc ttctttgcaa gggctgtcct gtacctgccg gggcgcccgc 360
 tcgaagcgtg gtcgcgcccg aggtactgaa aggaccaagg agctctggct gccctcagga 420
 40 attccaaatg accgaaggaa caaagcttca gggctctggg tgggtgtctcc cactattcag 480
 gaggtggtcg gaggtaacgc agcttcattt cgtccagtc tttccagtat taaagttgt 540
 tgtcaagatg ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaacatgt 600
 ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctctgaa tagtgggaga 660
 cacaccaga gcctgaagtt tgtccttcg

45 <210> 27
 <211> 471
 <212> DNA
 <213> Human

50 <400> 27

tcccagcggc atgaagtttg agattggcca ggccctgtac ctgggcttca tctccttcgt 60
 ccctctcgct cattgggtggc accctgcttt gcctgtcctg ccaggacgag gcaccctaca 120
 55 agccctaacc caggcccccgc ccagggccac cagcaccact gcaaacaccg cactgccta 180
 ccagccacca gctgcctaca aagacaatcg ggccccctca gtgacctcg ccaccacagc 240
 gggtagcaggc tgaacgacta cgtgtgagtc cccacagcct gcttctcccc tgggctgctg 300
 tgggctgggt cccggcgagg ctgtcaatgg aggcaggggt tccagcacia agtttacttc 360
 tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtctt tagagcacag 420
 60 ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a

<210> 28
 <211> 929
 <212> DNA
 <213> Human

65 <400> 28

5 ggtgaactca gtgcattggg ccaatgggtc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acggtttggc tgctgggtgg ctttcccctc actgtcattg gaggcattct 120
 tgggaagaac aacgccagcc cttttgatgc accctgtcgc accaagaaca tcgcccgga 180
 gattccaccc cagccctggg acaagtctac tgtcatccac atgactgttg gaggcttcct 240
 gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300
 gcagtacact ttgtacggca tcctctctct tgtcttcgcc atcctgctga gtgtgggggc 360
 ttgcatctcc attgcaactc cctacttcca gttgtctggg gaggattacc gctgggtggg 420
 10 gcgatctgtg ctgagtgttg gctccaccgg cctcttcac tcctctact cagttttcta 480
 ttatgcccg cgctccaaca tgtctggggc agtacagaca gtagagtctc tcggctactc 540
 cttactcact gggtatgtct tcttctcat gctgggcacc atctcctttt tttctccct 600
 aaagtctatc cggatatatct atgttaacct caagatggac tgagtctgt atggcagaac 660
 tattgtgtt ctctcccttt cttcatgccc tgtgaactc tcctaccagc ttctctctg 720
 attgactgaa ttgtgtgatg gcattgttgc cttccctttt tccctttggg cattccttcc 780
 15 ccagagaggg cctggaaatt ataaatctct atcacataag gattatata ttgaactttt 840
 taagtgtcct ttagttttgg tcctgatttt tctttttaca attaccaaaa taaaatttat 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa

<210> 29
 20 <211> 1775
 <212> DNA
 <213> Human

<400> 29

25 gaacgtgatg ggaacttttg gaggatgtct gagaaaaatgt ccgaagggat tttggccaac 60
 accagaaaac gccaatgtcc taggaattcc ctcccaaat gcttccaaa aaattactca 120
 ttgacaattc aaattgcact tggctggcgg cagcccgggc ggccttcagt cgtgtgggg 180
 30 cgcccgctg gccttctcct cgtaggactc cccaaactcg ttcactctgc gtttatccac 240
 aggataaagc caccgctggt acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300
 cagccggtga gacgtgggca tgggtgatgat gaaggcaag acgtcatcaa tgaagggtgt 360
 gaaagccttg taggtgaagg ccttccaggg cagatgtgcc actgacttca actttagt 420
 cacaagagc tggggcagca tgaagaggaa accaaaggca tagaccctgt tgacgaagct 480
 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540
 35 cccgacacag agagggtaca gcaggtatga caagtacttc atggcctgag tatcgtactc 600
 ctcggttttc ctctcagatt cgtgttaagt gccaaactga aattcgggca tcaggcctct 660
 ccaaaaaata gtcacttca atgccttctt cactttccac agctcaatgg cggctccaac 720
 acccgccggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780
 cacggtgctg aagcagcgcc agagcactgc cttggtggac atgccgatca tgctcttctt 840
 40 cttcttccag aaactgatgt catttttaaa ggccaggaaa tcaaagagaa gatggaacgc 900
 tgcgacaaag aaggtcagcg ccaggaagta taagtggta tctacaaaaa ttcctttcac 960
 ctcatcagca tctttctctg aaaaccgaa ctgctgcagg gactacacgg cgtcctgcat 1020
 gtggatccga aagcgcagcc gccccagtga gacctgtcgt taggacacgg tgaggggcag 1080
 45 ctcggtgggt gagcggttta tgaccatcag gtccttcacg cgggttgctga gctggtcgat 1140
 gaacaggatg ggcaggtaat gcacggtttt cccagctgg atcatcttca tgtaccgatg 1200
 cacatcgga ggcaggagg acccgctcaa gacaaagtgt tccgcatca cgttcagcgc 1260
 cagcccggt cgccagtggg acactggctc atccaggga ctcgtcggct tcttctcgc 1320
 ctcgatctgc tgtgtatcag actccccggg gagcagggtg atttcttctg gcttggggac 1380
 catgtagggt gtcagaggac tgaccagggt cactgtctc cgtcgtgcc acggcaggac 1440
 50 cccagcgtga tggaggaaga ttaggcata cagcgtccca ttgtttctcg ttttctttg 1500
 tacagaaaca ttaactgtcc tttaaaattt ggactccaca tcaaagtctt ccacattcaa 1560
 gaccaggtcg atgttgttct cagcaccag gtgggacctc gtcgtggtgt acacgctcag 1620
 ctgcagcttg ggccgcccgc ccaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680
 55 gcggtgtgac acgatgccgt acatgacca gcagggtgtg accacgtaga ccacgaacac 1740
 gccaccacc aagctggtga aggagctgcg gcccc

<210> 30
 <211> 1546
 <212> DNA
 60 <213> Human

<400> 30

65 aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgctaatt 60
 aaggccctgc caggctggga gggaattgtc cctgcctgct tctggagaaa gaagatattg 120

	acaccatcta	cgggcaccat	ggaactgctt	caagtgacca	ttctttttct	tctgcccagt	180
	atttgagca	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tggtgttact	240
	acaacaaaac	catctataac	aacaccaaac	acagaatcat	tacagaaaaa	tggtgtcaca	300
	ccaacaactg	gaacaactcc	taaagggaaca	atcaccaatg	aattacttaa	aatgtctctg	360
5	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaaag	ttccaaaccc	aagactgaaa	ctcagagttc	aattaaaaa	540
	acagaaatac	caggtagtgt	tctacaacca	gatgcatcac	cttctaaaac	tggtacatta	600
	acctcaatac	cagttacaat	tccagaaaac	acctcacagt	ctcaagtaat	aggcactgag	660
10	ggtggaaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgccc	720
	gtggttattg	ctttgattgt	aataacactt	tcagtatttg	ttctggtggg	tttgtaccga	780
	atgtgctgga	aggcagatcc	gggcacacca	gaaaatggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactct	900
	gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaattct	ctccacacct	aggcaataat	960
15	tacgcttaat	cttcagcttc	tatgcaccaa	gcgtggaaaa	ggagaaagtc	ctgcagaatc	1020
	aatcccgact	tccatacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagtgatg	1080
	tccagctgac	atgcaataat	ttgatggaa	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcggt	cctaggaaaa	ggaattttat	1200
	gaggagaatt	tgtgagcagt	gaatctgaca	gcccaggagg	tgggctcgct	gataggcatg	1260
20	actttccctta	atgttttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tggtcttata	ttacctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
	gcagggaaaa	gttgacagtg	tattattaaa	tattaggtag	aatcataacc	atgctacttt	1440
	gtacatatata	gtattttatt	cctgctttcg	tggtactttt	aataaataac	tactgtactc	1500
	aatactctaa	aaatactata	acatgactgt	gaaaatggca	aaaaaa		
25	<210> 31						
	<211> 750						
	<212> DNA						
	<213> Human						
30	<400> 31						
	cacttgggca	ccccattttt	ctaaaaaaat	ggaaatctgg	agggcaaaaa	aggtgtgctg	60
	aagggaagtg	cctctgatgg	cccaaaaacc	ttcttccaaa	ctagtgtagg	aatggaatgg	120
35	atagcaaatg	gatccttttt	ggcctccttt	ggagcatgcc	ttccctatct	tatccttggc	180
	cccactaaag	cagaacgtta	cggatatttc	tggttttgcc	attggatgcc	tatctggcca	240
	aacagccttt	ccctaattgg	aaaatgcagt	cctgtttaaa	acctttgatt	tacgactact	300
	tgtacatgct	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacatat	360
40	cagtgaacaa	tgacaagatc	ataaagaaca	gtatcatatt	attatttagt	cgcttttaca	420
	gtggcaagcc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagttatac	480
	ttttaatagc	ttcctcagca	cactatttcc	catgcattaa	atatgataaa	ataatctatc	540
	actgcccatc	ggctctgtaa	aaagggaagc	tgaatacaga	gccacacaac	ctaaaattgt	600
	ttttctagct	acaaagtata	gcatcatcaa	cacagacacg	atttggaactc	cctgacaggt	660
45	ggattggaaa	acggtgttta	aagagaagag	aacattttta	cataaatgtc	attaagaatc	720
	ccaaaggcct	tatttgcac	caccgtcccc				
	<210> 32						
	<211> 1620						
	<212> DNA						
	<213> Human						
50	<400> 32						
	gcaattcccc	cctcccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
55	gtgcagccat	tcataagaac	cttggtgccc	cagaaaaatc	tgctcttttt	ggtaccaaac	120
	ctgaggtctt	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttggtca	180
	atctgtgcaa	actctgatga	tacctgcctt	atgtggattc	ttttccacac	tgctttcatt	240
	tttaagtata	aagacttaga	aaactagaat	aatgctttta	caaataatta	aaagtatgtg	300
	atgttctggg	ttttttcctt	cttttttaga	ccccgcctcc	atttaaaaaa	ttaaaaaaa	360
60	aaaaaaaact	tttaacattt	aaaaaataaa	aattaacaaa	atttcactta	ttccaggaca	420
	cgctggcatt	tggactcaat	gaaaagggca	cctaaagaaa	ataaggctga	ctgaatgttt	480
	tcataatttt	tcacacaata	acagtcctct	tctatccagc	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgcccaga	aagtacctga	gctatcagtg	600
	attggaatgg	cacaggaaac	cgaatcacat	gggtgcccctc	cccttggttt	tcaagtatct	660
65	tgaggtttgt	cacaaaaatt	aggctatgcc	ttcagtgctc	tggtctttta	acctaccctt	720
	tgacaatcag	gtgctaata	ttgtatacta	ttaaaaccag	cacataagta	ttgtaaatgt	780

	gtgttcctcc	taggttgga	gaaatgtctt	tccttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgatttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gtttggcatg	atcatcattc	tcgatgatat	tctcactttg	960
	tcgcaaatct	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
5	cagtattatg	tttacaatcc	attggatgag	tgcagcatta	taagaccttg	gtgcccagaa	1080
	aaatctgtcc	tttttggtac	caaacctgag	gtcttttgga	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaactctg	tgcaaaactct	gatgatacct	gcttatgtgg	1200
	attctttttc	acactgcttt	catttttaag	tataaagact	tagaaaacta	gaataatgct	1260
	tttacaata	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaacctgt	1320
10	atttaaacia	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	cttctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtatttg	tgttcctaata	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcat	aaacaacact	tccccttgag	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaat	gtgtaactta	agggatttat	atatataaat	1560
	acatatatac	ctttgtaacc	tttatactgt	aaataaaaaa	gttgctttag	tcaaaaaaaa	1620
15	<210> 33						
	<211> 2968						
	<212> DNA						
	<213> Human						
20	<400> 33						
	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
25	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggaggga	120
	gaaagtgaag	gcagtgaagg	tgatgaggaa	gatgaaaagg	tgtcagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaagtaaa	gaaatgagct	cagatttctga	atatgactct	240
	gatgatgac	ggactaaaga	agaaagggt	tatgacaaag	caaaacggag	gattgagaaa	300
	cggcgacttg	aacatagtaa	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
30	gtacttgggc	atgtggacac	aggaagaca	aaaattctag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagg	tgttatcaca	caacaaattg	gggccaccaa	tgttcctctt	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtacggatt	540
	ccaggaatgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
	ggaagctctc	tttgtgacat	tgccatttta	gttgttgata	ttatgcatgg	tttgagagccc	660
35	cagacaattg	agtctatcaa	ccttctcaaa	tctaaaaaat	gtcccctcat	tggtgcactc	720
	aataagattg	ataggttata	tgattggaaa	aagagtcctg	actctgatgt	ggctgctact	780
	ttagaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	ctttgtgacc	tacctctgca	catactggtg	atggcatggg	aagtctgac	960
40	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgacac	ctgtgaagag	1020
	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tgggcaccac	tatagatgac	1080
	atcttgatca	atgggcgttt	gaaggagga	gatataatca	ttgttcctgg	agtagaagg	1140
	cccattgtaa	ctcagattcg	aggcctcctg	ttacctctc	ctatgaagga	attacgagtg	1200
	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	agggggtaaa	gattcttgga	1260
	aaagacctgg	agaaaacatt	ggctgggtta	cccctccttg	tggcttataa	agaagatgaa	1320
45	atccctgttc	ttaaagatga	attgatccat	gagttaaagc	agacactaaa	tgctatcaaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttctttgga	agctctactg	1440
	gaatttctga	aaacatcaga	agtgccttat	gcaggaatta	acattggccc	agtgcataaa	1500
	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagttt	aggagttaga	1620
50	atttttagtg	cagaaattat	ttatcattta	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaattttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agtacatttt	taattctcga	gatccgatag	tgatgggggt	gacggtggaa	1800
	gcaggtcagg	tgaacacagg	gacacccatg	tgtgtcccaa	gcaaaaattt	tggtgacatc	1860
55	ggaatagtaa	caagtattga	aataaacatt	aaacaagtgg	atggtgcaaa	aaaaggacaa	1920
	gaagtttttg	taaaaataga	acctatccct	ggtgagtcac	ccaaaatggt	tggaagacat	1980
	tttgaagcta	cagatattct	tgtagtaag	atcagccggc	agtccattga	tgactcaaaa	2040
	gactggttca	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
	gtatttgaaa	tcactctaatt	ttttcacatg	gagcaggaac	tggagtaaat	gcaatactgt	2160
	ggttgtaaat	cccaacaaaa	atcagacaaa	aatggaaca	gacgtatttg	gacactgatg	2220
60	gacttaagta	tggaagggaag	aaaaataggt	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	ggtttgacag	tggtcagtta	catgtcccca	cagttccaat	gtgcctgttc	2340
	actcacctct	cccttcccca	acccttctct	acttggctgc	tgttttaaaag	tttgcccttc	2400
	cccaaatttg	gattttttatt	acagatctaa	agctottttcg	attttatact	gattaaatca	2460
	gtactgcagt	atttgattaa	aaaaaaaaaa	gcagatttttg	tgattcttgg	gacttttttg	2520
65	acgtaagaaa	tacttcttta	tttatgcata	ttcttccac	agtgattttt	ccagcattct	2580
	tctgccatat	gccttttaggg	cttttataaa	atagaaaatt	aggcattctg	atatttcttt	2640

agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700
 agtcacgagt ccatttgaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760
 catccaccag taagcaagct ctgttaggct tccatgggta gtggtagctt ctctcccaca 2820
 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880
 5 ggtatgccag cacctgggta acagtaggag attttataca ttaatctgat ctgtttaatc 2940
 tgatcggttt agtagagatt ttatacat

<210> 34

<211> 6011

10 <212> DNA

<213> Human

<400> 34

15

acggggcgcc ggacgaccgc cacatcttat cctccacgcc ccaactcgac tcggagcggg 60
 accgccccgc actccccctc gggccggcca ctgagaggag gaggagagag gccgcccggc 120
 20 cggcttgagc cgagcgcagc acccccgcgc ccccgcgcca gaagtttggg tgaaccgggc 180
 tgccgggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggaggagg 240
 ggaactcccc cggcccaagg ctctgtgggt cggggtcgcg cggccgcaga aggggcccgg 300
 tccgccccgc aggggagcgc cccccgggga cccgagaggg gggtagggac cgcgggctgc 360
 tgggtcgggc gcggcagcgt gtgccccgcg caggggaggc gccgccccgc tcccggcccg 420
 25 gctgcgagga ggaggcggcg gcggcgagag aggatgtact tggtaggggg ggacaggggg 480
 ttggccggct gcgggcacct cctgggtctcg ctgctggggc tgctgctgct gccggcgcg 540
 tccggcaccg gggcgctggg ctgcctgccc tgtgacgagt ccaagtgcga ggagcccagg 600
 aaccgccccg ggagcatcgt gcagggcgtc tgcggctgct gctacacgtg cgcagccag 660
 gggaacgaga gctgcggcgg caccttcggg atttacggaa cctgcgaccg ggggctgctg 720
 30 tgtgtcatcc gcccccgct caatggcgac tccctcaccg agtacgaagc gggcgcttgc 780
 gaagatgaga actggactga tgaccaactg cttggtttta aaccatgcaa tgaaaacctt 840
 attgtggct gcaataaat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900
 aatccctttg agtttccaag tcaggatatg tgcctttcag ctttaaagag aattgaagaa 960
 gagaagccag attgtccaa ggcccgctgt gaagtccagt tctctccagc ttgtcctgaa 1020
 35 gattctgttc tgatcgaggg ttatgtcctt cctggggagt gctgtccctt acccagccgc 1080
 tgcgtgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140
 ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaacca 1200
 gttttcggcg tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260
 ccggacagct atgaaactca agtcagacta actgcagatg gttgtgtgac tttgccaaca 1320
 40 agatgcgagt gtctctctgg cttatgtggg ttcccctgtg gtgaggtggg atccactccc 1380
 cgcatagtct ctctgtggcg tgggacacct ggaaagtgtc gtgatgtctt tgaatgtgtt 1440
 aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500
 cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcc 1560
 cagtgtgtgt agataaactg cgagagggtac tacgtgcccc aaggagagtg ctgcccagtg 1620
 45 tgtgaagatc cagtgtatcc ttttaataat cccgctggct gctatgcaa tggcctgatc 1680
 cttgccacag gagaccgtg gcgggaagac gactgcacat tctgccagtg cgtcaacggt 1740
 gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcattg 1860
 ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggttt caaacgcgat 1920
 50 cacaatgggt gtcggacctg tcagtgcata aacaccagg aactatgttc agaacgtaaa 1980
 caaggctgca ccttgaactg tcccttcggg ttccctactg atgccccaaa ctgtgagatc 2040
 tgtgagtgcc gcccaaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100
 cttggattgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160
 ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtcacgg ctgtcttatc 2220
 55 tgcaagtgca gagagccctc tgcttcagct gggccaccca tctgtcggg cacttgtctc 2280
 accgtggatg gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340
 tactgtctca atggacggga aatgtgtgcc ctgatcacct gcccggtgcc tgcctgtggc 2400
 aacccaccca ttcaccctgg acagtgtgc ccacatgtg cagatgactt tgtgtgtcag 2460
 aagccagagc tcagtactcc ctccatttgc cacgcccctg gaggagaata ctttgtggaa 2520
 60 ggagaaacgt ggaacattga ctctgtact cagtgcacct gccacagcgg acgggtgctg 2580
 tgtgagacag aggtgtgccc accgctgtct tgccagaacc cctcacgcac ccaggattcc 2640
 tgctgcccac agtgtacaga tcaacctttt cggccttcc tgtcccgcaa taacagcgta 2700
 cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760
 gacgtttgta ccagctgcat ctgcattgat agcgttaatta gctgtttctc tgagtcctgc 2820
 65 cctctgtgat cctgtgaaag acctgtcttg agaaaaggcc agtgtgttcc ctactgcata 2880
 aaagacacaa ttccaaagaa ggtgggtgtc cacttcagtg ggaaggccta tgccgacgag 2940

gagcgggtggg accttgacag ctgcacccac tgctactgcc tgcagggcca gaccctctgc 3000
 tgcaccgtca gctgcccccc tctgcccgtg gttgagccca tcaacgtgga aggaagtgc 3060
 tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120
 aaccatcgag gagaggttga cctggaggtt cccctgtggc ccacgcctag tgaaaatgat 3180
 5 atcgtccatc tccctagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240
 cacccaagtg aagattcttc actggactcc attgcctcag ttgtggttcc cataattata 3300
 tgccctctcta ttataatagc attcctattc atcaatcaga agaaacagtg gataccactg 3360
 ctttgctggg atcgaaacacc aactaagcct tcttccctaa ataatacagct agtatctgtg 3420
 gactgcaaga aaggaaccag agtccaggtg gacagttccc agagaatgct aagaattgca 3480
 10 gaaccagatg caagattcag tggcttctac agcatgcaaa aacagaacca tctacaggca 3540
 gacaatttct accaaacagt gtgaagaaag gcaactagga tgaggtttca aaagacggaa 3600
 gacgactaaa tctgtcttaa aaagtaaaact agaatttgtg cacttgctta gtggattgta 3660
 ttggattgtg acttgatgta cagcgctaag accttactgg gatgggctct gtctacagca 3720
 atgtgcagaa caagcattcc cacttttcct caagataact gaccaagtgt tttcttagaa 3780
 15 ccaaagtttt taaagtgtct aagatatatt tgccgtgaag atagctgtag agatatttgg 3840
 ggtggggaca gtgagtttgg atggggaaag ggggtgggag gtggtgttgg gaagaaaaat 3900
 tggtcagctt ggctcgggga gaaacctggg aacataaaaag cagttcagtg gccagagggt 3960
 tatttttttc ctattgctct gaagactgca ctggttgctg caaagctcag gcctgaatga 4020
 gcaggaaaca aaaaaggcct tgcgacccag ctgccataac caccttagaa ctaccagacg 4080
 20 agcacatcag aaccctttga cagccatccc aggtctaaag ccacaagttt cttttctata 4140
 cagtccacaac tgcagtaggc agtgaggaag ccagagaaat gcgatagcgg catttctcta 4200
 aagcgggtta ttaaggatat atacagttac actttttgct gcttttattt tcttccaagc 4260
 caatcaatca gccagttcct agcagagtca gcacatgaac aagatctaag tcatttcttg 4320
 atgtgagcac tggagctttt tttttttaca acgtgacagg aagaggaggg agagggtgac 4380
 25 gaacaccagg catttccagg ggctatatatt cactgtttgt tgttgctttg ttctgttata 4440
 ttgttggttg ttcattagttt ttgttgaagc tctagcttaa gaagaaactt tttttaaaaa 4500
 gactgttttg ggattctttt tccttattat ataactgattc taaaaaatag aaactacttc 4560
 attttaattg tatattattc aagcaccttt gttgaagctc aaaaaaaatg atgcctcttt 4620
 aaacttttagc aattatagga gtatttatgt aactatctta tgcttcaaaa aacaaaagta 4680
 30 tttgtgtgca tgtgtatata atatatatat atacatatat atttatacac atacaattta 4740
 tgttttctcg ttgaatgtat ttttatgaga ttttaaccag aacaaaggca gataaacagg 4800
 cattccatag cagtgccttt gatcacttac aaattttttg aataacacaa aatctcattc 4860
 tacctgcagt ttaattggaa agatgtgtgt gtgagagtat gtatgtgtgt gtgtgtgtgt 4920
 35 gtgtgtgcgc gcgcacgcac gccttgagca gtcagcattg cacctgctat ggagaagggt 4980
 attcctttat taaaatcttc ctcatgttga tttgctttca gttgggtttc aatttgctca 5040
 ctggccagag acattgatgg cagttcttat ctgcatcact aatcagctcc tggatttttt 5100
 tttttttttt tcaacaatg gtttgaaaca actactggaa tattgtccac aataagctgg 5160
 aagtttgttg tagtatgcct caaatataac tgactgtata ctatagtgtt aacttttcaa 5220
 acagccctta gcacttttat actaattaac ccatttgtgc attgagtttt cttttaaaaa 5280
 40 tgcttgttgt gaaagacaca gataccaggt atgcttaacg tgaaaagaaa atgtgttctg 5340
 ttttgtaaaag gaactttcaa gtattgttgt aaatacttgg acagaggttg ctgaacttta 5400
 aaaaaaatta atttattatt ataattgacct aatttattaa tctgaagatt aaccattttt 5460
 ttgtcttaga atatcaaaaa gaaaaagaaa aaggtgttct agctgtttgc atcaaaggaa 5520
 aaaaagattt attatcaagg ggcaatattt ttatcttttc caaaataaat ttgttaatga 5580
 45 tacattacaa aaatagattg acatcagcct gattagtata aattttgttg gtaattaatc 5640
 cattcctggc ataaaaagtc tttatcaaaa aaaattgtag atgcttctt tttgtttttt 5700
 caatcatggc catattatga aaatactaac aggatatagg acaagggtga aattttttta 5760
 ttattatttt aaagatatga tttatcctga gtgctgtatc tattactctt ttacttttgt 5820
 tcctgttgtg ctcttgtaaa agaaaaatat aatttcctga agaataaaat agatatatgg 5880
 50 cacttgaggt gcatcatagt tctacagttt gtttttgttt tcttcaaaaa agctgtaaga 5940
 gaattatctg caacttgatt cttggcagga aataaacatt ttgagttgaa atcaaaaaaa 6000
 aaaaaaaaaa a

55 <210> 34a
 <211> 1036
 <212> DNA
 <213> Human

60 <400> 34a

65 mylvagdrql agcghllvsl lgllllpars gtralvclpc deskceepn rpgsivqgvc 60
 gccyptcasqg nescggtfgi ygtcdrglrc virpplngds lteyeagvce denwtddqll 120
 gfkpcnenli agcniingkc ecntirtcsn pfefpsqdmc lsalkrieee kpdcskarce 180
 vqfspirped svliegyapp gecceplpsrc vcnpagclrk vcqpgnlnil vskasgkpge 240

5 ccdlyeckpv fgvdertvec ptvqqtacpp dsyetqvrllt adgcctlptr cecslgclcgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgdmfrr mdncrfrcrq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 ctfcqcvnge rhcvatvcgq tctnpvkvpq eccpvceep iitvdppacg elsnctltkr 480
 dcingfkrdh ngcrtcqcin tqelcserkq gctlncpfgf ltdaqlnceic ecrprpkkr 540
 piicdkycpl gllknkhgdc icrckkcpel scskicplgf qgdshgcllc kcreasasag 600
 ppilsgtclt vdghhhknee swhdgcrecy clngremcal itcpvpacgn ptihpggqccp 660
 scaddfvvqk pelstpsich apggeyfvge etwnidsctq ctchsgrvlc etevcppllc 720
 10 qnpsrtqdsr cpqctdqfpr pslsrnnsvp nyckndegdi flaaeswkp dvtscicids 780
 viscfesep svscerpvlr kgqccpycik dtipkkvch fsgkayadee rwdldscethc 840
 yclgggtlcs tvscplpcv epinvegscc pmcpemyvpe ptnipiekt hrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrh psedssldsi asvvvpiiic lsiiiaflfi 960
 nqkkqwipll cwyrtptkps slnnqlvsd ckgtrvqv d ssqmlriae pdarfsgfys 1020
 15 mqkqnhlqad nfyqtv

<210> 35

<211> 716

<212> DNA

20 <213> Human

<400> 35

25 gcagtagctg gagggtcctg cagggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60
 acccggggct cctggggcgc tctgcccggc tggggctgag cagcgatcct gctttgtccc 120
 agaagtccag agggatcagc cccagaacac accctcctcc cggggacgac gcagctttct 180
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240
 ccagaactcg gtcctatttt acagattgag aaactatggt tcaagaagag aggacggggc 300
 30 ttgagggaat ctctgatctc tcttatatg acctcaaaact gaccatacta aacagtgtag 360
 aagggtcttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaga 420
 gtcagtgtgg agtagacggg ttctccacc cagggttgac tcagggggat gatctgggtc 480
 ccattctggt cttaagacc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 tctggttagt gtcgtaacct ctgtgtgctt cccgttacc catctgtcca gtgagctcag 600
 35 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttcctt ccacatcaaa aaaaaa

<210> 36

<211> 395

40 <212> DNA

<213> Human

<400> 36

45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca ttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180
 atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240
 gccagtaaaa accaaagtca gggtaaccaa tgtcatttta caaaatgtta aaaccctaata 300
 50 tgcagttcct tttttaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

<210> 37

<211> 134

55 <212> DNA

<213> Human

<400> 37

60 ccctcgagcg gccgcccggg caggtagctt taccaccgaa ttgttcactt gactttaaga 60
 aaccataaaa gctgcctggc tttagcaaac aggcctatca acaccatggt gacttccat 120
 aaggacacc gtgt

<210> 38

65 <211> 644

<212> DNA

<213> Human

<400> 38

5 aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcgggc gaggtagagg 60
 cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
 gggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180
 ggaatattgg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
 gcttgggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300
 10 ttcagagcca ggctgtaaaa attaaatga acaaattacg gcaaagtttt aggagaaaaga 360
 aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
 ttgcaccggg aaaaatgtagc ttcccgggta agtaccttgg ccatgtagaa gttgatgaat 480
 caagagggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagtctt 540
 tcaaaggctt ctttggaaaa actggaaaaga aagcagttaa agcagtttct gtgggtctaa 600
 15 gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

25 ctttttgttt gggttttcca atgtagatgt ctcaagtgaat tgtgcagata tactttgttc 60
 cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120
 gcctcccac taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
 tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
 acctgtctcg tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
 agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360
 30 tggtcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
 ttttttgttt ttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480
 aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
 taagaaatc tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600
 atgtttgctt caatagaaat ttgttccac ttgtattttc aacaaaatta tcggaac

<210> 40

<211> 1328

<212> DNA

<213> Human

40

<400> 40

acaattttaa aataactagc aattaatcac agcatatcag gaaaaagtac acagtgagtt 60
 45 ctggttagtt tttgtaggct cattatgggt agggtcgtta agatgtatat aagaacctac 120
 ctatcatgct gtagtatca ctcatccat tttcatgttc catgcatact cgggcatcat 180
 gctaataatgt atccttttaa gcactctcaa ggaaacaaaa gggcctttta tttttataaa 240
 ggtaaaaaaa attcccaaaa tattttgcac tgaatgtacc aaagggtgaag ggacattaca 300
 atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
 acttccttca cagtgccttg tctaccacta caaggactgt gcatctaagt aataattttt 420
 50 taagattcac tatatgtgat agtatgatat gcatttattt aaaatgcatt agactctctt 480
 ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540
 gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600
 tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaattgaa 660
 actcagaact atattttctaa gcctgcattt tcaactgatgc ataattttct tagtaatttt 720
 55 aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780
 ttaattttat gagaaggat tcttcatttt aattgctttt gggattactc cacatctttg 840
 tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaagc 900
 attggattga catatgggtt gccagcctat ggggttacag gcattgccc aacatttctt 960
 60 tgagatctat atttataagc agccatggaa ttcttattat gggatgttgg caatcttaca 1020
 ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
 gtgagtttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttactctc 1140
 ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggt tatagaaatc 1200
 tggaaataag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
 65 ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
 tgaaaaaa

<210> 41
<211> 987
<212> DNA
<213> Human

5
<400> 41

10 aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgtagg caggtaacat 60
tgagctcttt tcaaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatggtagg 120
taacccccgg ctatcagttc ggatgggtgc caccctcctt gctgtaggat ggaagcagcc 180
atggagtggg agggaggcgc aataagacac cctccacag agcttggcat catgggaagc 240
tggttctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300
tgtctttctc ttctccaacc aacagaaaag actgctcttc aaagggtggag ggtcttcattg 360
aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaaagg agggcacaca 420
15 ggaggaggga ggagctggta ggagatgct ggctttacct aaggctctga aacaaggagg 480
gcagaatagg cagaggcctc tccgtcccag gcccattttt gacagatggc gggacggaaa 540
tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
gaacaagcac aggccttgga atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
20 tgaggcttgt gatacctgtt ttgaaggggt gctgagaaaa ttaaagataa gggatatcaa 780
aatagttctac ggccatacca ccctgaacgt gcctaattctc gtaagctaag caggggtcagg 840
cctgggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgag ttggagtttg 900
actctgtctt aacagtagcg tggcacacag aaggcactca gtaataactt gttgaataaa 960
tgaagtagcg atttggtgtg aaaaaaa

25
<210> 42
<211> 956
<212> DNA
<213> Human

30
<400> 42

35 cggacgggtg ggcggacgcy tgggtgcagg agcaggggcg ctgccgactg ccccaaccaa 60
ggaaggagcc cctgagtcct cctgcgcctc catccatctg tccggccaga gccggcatcc 120
ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180
tcaggggatg tttacctggt gctcgggaag ggaggggaa gggccgggga gggggcacgg 240
caggcgtgtg gcagccacac gcaggcggcc agggcgggca gggacccaa gcaggatgac 300
cacgcacctc cagccactg cctccccga atgcatttgg aaccaaagtc taaactgagc 360
tcgcagcccc cgcgcctcc ctccgcctcc catcccgctt agcgtcttgg acagatggac 420
40 gcaggccctg tccagcccc agtgcgctcg ttccggtccc cacagactgc cccagccaac 480
gagattgctg gaaaccaagt caggccaggg gggcggaaca aaggggcagg tgcggcctgg 540
ggggaacgga tgctccgagg actggactgt ttttttcaca catcggtgac gcagcgggtg 600
gaaggaaagg cagatgtaaa tgatgtgttg gtttacaggg tatatttttg atacctcaa 660
tgaattaaat cagatgtttt acgcaaggaa ggacttacct agtattactg ctgctgtgct 720
45 tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcggtg accccatcac 780
tcgcaggacc aaggggggcg ggactgctgg ctcacgcccc gctgtgtcct cctccctc 840
ccttccttgg gcagaatgaa ttcgatgcgt attctgtggc cgccatctgc gcagggtggg 900
ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

50
<210> 43
<211> 536
<212> DNA
<213> Human

55
<400> 43

60 aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60
cccctagttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120
agtgttagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180
60 ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240
tctaaataaa gacatttgaa ggggttagtt gaattctaaa agtaggtaat agccaaatag 300
cattctcctc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360
attttttcca gatgaaactt gtgccacttc caattgacta atgaaataca aggagacaga 420
ctggaaaaag tgggttatgc caccttttaa accctttctg gtaaatatta tggtagttaa 480
65 aggggtggtt ccccggcacc tggacctgga caggtagggg tccgtgggta accagt

<210> 44
<211> 1630
<212> DNA
<213> Human

5

<400> 44

10 ggggagggac gagtatggaa ccctgaagggt agcaagtcca ggcaactggcc tgaccatccg 60
gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180
atccctctcg gaggggaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240
ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
gtgatttccc ttagggcccag gacttgggcc tccagctcat ctgttccttc tggggccatt 360
catggcagggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
15 gactttacct gattgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480
tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600
attaggaaagt cgggggtggg tgggtgggtt gggctagtgt ggtttgaatt taggggcca 660
tgagcttggg tacgtgagca ggggtgttaag ttagggtctg cctgtatttc tgggtcccct 720
20 ggaaatgtcc cttcttcag tgtcagacct cagtcccagt gtccatatcg tgcccagaaa 780
agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgccctgg 840
gcccagtgac ctgggggagc ctggctgcag gccctcactg gttccctaaa ccttgggtggc 900
tgtgattcac gtccccaggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960
gagttggctg gtagagcctt cttagaggtt agaataatag cttcaggatc agctgggggt 1020
25 atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
tgagggacag tttgggtttg ggacttacca ggggtgatgt agatctggaa cccccaagt 1140
aggctggagg gagttaaggc cagtatggaa gatagggttg ggacagggtg ctttggaatg 1200
aaagagtgc ctttagagggc tccttgggcc tcagggaatgc tcctgctgct gtgaagatga 1260
gaaggtgtc ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320
30 ctgggtccct ttagcacag gagactggg ctaagggcc ctcccaggga agggacacca 1380
tcaggcctct ggctgaggca gtagcataga ggatccattt ctacctgcat ttcccagagg 1440
actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgctg gctgttctct 1500
cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtctg 1560
35 cctcttgct cttgtagaat gcagctctgg ccctcaataa atgcttctg cattcatctg 1620
caaaaaaaaa

<210> 45
<211> 169
<212> DNA
<213> Human

40

<400> 45

45 tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60
taaaactggt ttatgatctt cagtctgatt ccagtgtgc ataactagat aacgtatgaa 120
ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaaga cttagtga

<210> 46
<211> 769
<212> DNA
<213> Human

50

<400> 46

55 tgcaggctcat atttactatc ggcaataaaa ggaagcaaag cagtattaag cagcgggtga 60
atttgtcgct ttcacttttt ataaagtgtt acataaaatg tcatatttcc aaatttaaaa 120
acataactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaaa 180
aaacaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataga 240
60 aaggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300
ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
ggccagctcc tttcctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480
catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540
tattttgtaa taaaatcaaa ttcccattg aaaccttcaa aaactttgca gaatgaggtt 600
65 ttgatatatg tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660
cctgcctttt tgtttttaaa aatgaagact atcattgaaa caagtttgc ttcagtatca 720

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47
 <211> 2529
 <212> DNA
 <213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaaca 60
 gtgaaaatta gtgactgggt aaggtgtgccc actgtacata tcatcatttt ctgactgggg 120
 tcaggacctg gtcctagtcc acaaggggtg caggaggagg gtggaggcta agaacacaga 180
 aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
 15 ggatgggtgg aaggggggtc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
 gccttactta gctcctggca gaggtgagt ggggacctac gaggttcaaa atcaaatggc 360
 atttgccag cctggcttta ctaacaggtt ccagagtgc ctctgttggc tgagctctcc 420
 tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480
 attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcct ctctccctcc 540
 actagttggg gccactgcac tgagggggggt cccaccaatt ctctctagag aagagacact 600
 20 ccagaggccc ctgcaacttt gcggatttcc agaaggtgat aaaaagagca ctcttgagt 660
 ggtgccagg aatgttttaa atctatcagg cactactata agctgggtgg ttcttcctac 720
 caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaacac 780
 tgaactctgg tgttgacagg tacaaggagg aagagatggg gactgtgaag aggggagggc 840
 ttcctcctc ttcctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900
 25 gcaatagatg gggcttcccta ccatttgttg gttattgctg gggtagcca ggagcagtg 960
 ggatggcaaa gtaggagaga ggcccagagg aaagcccac tccctccagc tttgggggtct 1020
 ccagaaagag tctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
 aggtgaacag tccctacctgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140
 ttatgaaact gaaaatcaaa tcaaggtatt ggaagaata atttccctc gattccacag 1200
 30 gaggaagac cacacaatat cattgtgctg gggctcccca aggcctgcc acctggcttt 1260
 acaaatcatc aggggttgcc tgcttgccag tcacatgctt ccctggtttt agcacacata 1320
 caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380
 ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatgggtg tcttttgcac 1440
 gcagttgggc tgacctgaca aagccccagc tttcctgttg caggttctgg gagaggatgc 1500
 35 attcaagctt ctgcagccta ggggacagg ctgctgttcc agttattact gcctcggagc 1560
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
 cttcggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680
 agggagaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
 tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
 40 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
 gggggagtgg gagggggaag aaagagaaca gagcgccact gggatttgaa aggggaacct 1980
 ctctatctga ggagccccca ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
 tgaaaatttc cagaaatacc atttggtgca tccctttgtt tctgtaatat taaactcagg 2100
 45 tgaaattata ctctgacagt ttctctcttt ctgctcttcc cctctgcaga gtcaggacct 2160
 gcagaaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaaag 2220
 gcctgaagtt atagagtgtt tacagcgtg gcgatatcca ggggtcatcg ccaactggtc 2280
 tcgagtcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340
 ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtcacca 2400
 50 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
 ggggtgtcc

<210> 48
 <211> 1553
 <212> DNA
 <213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
 ttcatatata tatatacata catatataaa ggaaacaatt tgcaaattta cacacctgac 120
 aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
 ctagccaggc ccgtttttcca tccctaagta ccattctctc atttgggccc ttctaggggt 240
 65 ggggccctga gcttgggttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
 tgaaggacag tgtagacctc atctttgtct gtccccgct gcctttcagt ttacagtgat 360

5 ccatcaagag ggctatggga gccaaagtga caccgggggat tgaggctaata tcacctgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttctttt ttttctcga 480
 gacggagtct cgctgtgttg cccaggctgg agtgcagtgg caccgtctcg gctcactgca 540
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600
 taggtgccaa ccaactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgcccgcct cggcctccca 720
 aagtgtctggg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780
 atgacaccag ttccctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 agacaggagg gtgggtggcag caaactgca gctgcttctg gatgctgctg ggggtgcttc 900
 10 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 acttcagtgg tgcacctgga tgggtggaagc cagccttttg ggcaggaaac cagctcagag 1020
 aggtacccca gctcagctgc tggcaggagc caggtattta cagccataat gtgtgtaaag 1080
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140
 ggatgagctt cactcaacgt ggagatggtg gtggactggt cctgaaaag cgggccttgc 1200
 15 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
 cgaggggagc agggaggcttc tctctagtcc ctttgagggc tttggctgag agaagagtga 1320
 gcagggagct gggaaatggtc caggcaggga agggagctga agtgattcgg ggctaagtcc 1380
 tcagatcgat gtatttctct ccttggtctc ccggagccct cttgtcaccg ctgctgccct 1440
 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500
 20 tacgagaccg ggggtagcgt gatctcctgc ttcctgagc gcctgcacgg cag

<210> 49

<211> 921

<212> DNA

25 <213> Human

<400> 49

30 ctgtgggtccc agctactcag gaggtgagg cgggaggatt gcttgagccc aggagttaga 60
 tggtgcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataacct 120
 gtctcagaaa acaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180
 gctgtcaga acacttggt actcctaccc cagatcagtg gacctgggaa tgagggttgg 240
 tcccgggagg cttttctcca agctgttgcc accagaccgg ccattgggaa cctggccaca 300
 gaagcctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360
 35 ggagggtggg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatt ggcaagcatg 420
 tgcgtgcctg tgtgtgtgcg tgcccctccc ctgcagccgt cgggtgtatc tccctccagc 480
 cccttcgcca ccttctgagc attgtctgtc cactgtgagc tgcccagaga cagcagact 540
 ccacgtggtt ttaaggggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600
 cagggtgctaa atgaccggac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660
 40 gtcccgcgtga cctgcccccg tggcgtctca cgggtgatgcc tgctcctgac attggtgttc 720
 actgtagcaa actacattct ggatgggaat ttcatgtac atgtgtggca tgtggaaaat 780
 tcaaaataaa atggacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgga 840
 tactttgacc tcttgcttac aaccctctcc ttgggtccga ggctggtagc tttgttcaat 900
 45 tcagatggtt gggggcgggt g

<210> 50

<211> 338

<212> DNA

<213> Human

50

<400> 50

55 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60
 tcccttccag atattacccc atttctctac ttcccattgt agccaaactt tccaaaaatt 120
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc acccctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgatac catactcaat gatccttcgt 240
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgcatac 300
 gtaagaaaact ttctttcttg aattcttggt tctcttgg

60

<210> 51

<211> 1191

<212> DNA

<213> Human

65

<400> 51

5 ctagcaagca ggtaaacgag ctttgtacaa acacacacag accaacacat ccggggatgg 60
 ctgtgtgttg ctagagcaga ggctgattaa acactcagtg tggtggctct ctgtgccact 120
 cctggaaaat aatgaattgg gtaaggaaca gttataaga aaatgtgcct tgctaactgt 180
 gcacattaca acaaagagct ggcagctcct gaaggaaaag ggcttggtgcc gctgccgttc 240
 10 aaacttggtca gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300
 tacatgtgtc tgtctggcct gatctgtgca tctgctcgga gacgctcctg acaagtcggg 360
 aatttctcta tttctccact ggtgcaaaga gcggatttct ccctgcttct cttctgtcac 420
 ccccgctcct ctcccccagg aggcctcctg atttatggta gctttggact tgcttccccg 480
 tctgactgtc cttgacttct agaattggaag aagctgagct ggtgaaggga agactccagg 540
 15 ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600
 aagacaaact aaagcaccag catttgaaga aaaaggcctt gagggagaaa tggcttctag 660
 atggaatcag cagcggaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780
 aaaaagctga actgcaaatc tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840
 20 ttgagcggag aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900
 aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacatacctt 960
 ctaggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020
 tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaagt acagttctgt 1080
 cttccaatac ctctggccat cagatgactt taaaagggtac aggagtaaaa gtttaagatg 1140
 atgggcacaaa gtccagtgtg ttcagtaaag tgctaatacac aagttggagg t

<210> 52
 <211> 1200
 <212> DNA
 25 <213> Human

<400> 52

30 aacagggact ctactctat caacccagg ctggagtccg gtgcgcccac cctggctccc 60
 tgcaacctcc gcctcccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120
 actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacagggttt 180
 cgcttctgt ccaggccggc atcatatact ttaaatcatg ccagatgac ttaatacct 240
 aatacaatat atcaggttgg tttaaaaata attgctttt tattattttt gcatttttgc 300
 35 accaacctta atgctatgta aatagtgtt atactgttgc ttaacaacag tatgacaatt 360
 ttggcttttt ctttgtatta ttttgtattt ttttttttta ttgtgtggtc tttttttttt 420
 ttctcagtggt tttcaattcc tccttggttg aatccatgga tgcaaaaccc acagatatga 480
 agggctggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540
 atatgtagtg aaagttaatg tacagtggaa agagtagttg aaaacataaa catttggacc 600
 40 tttcaagaaa ggtagcttgg tgaagttttt caccttcaaa ctatgtccca gtcagggtc 660
 tgctactaat tagctataat ctttgacaaa attacatcac ctttgagtct cagttgcctc 720
 acctgtaaaa tgaaagaact ggatactctc taaggtcact tccagccctg tcattctata 780
 actctgttat gctgaggaag aaattcacat tgtgttaact gtatgagtca aactgaaaat 840
 gattattaaa gtgggaaaaa gccaatgtct tctcttagaa agctcaacta aatttgagaa 900
 45 gaataatctt ttcaattttt taagaattta aatattttta agggtttgac ctatttattt 960
 agagatgggg tctcactctg tcacccagac tggagtacag tggcacaatc atagctcact 1020
 gctgcctcaa attcatgggc tcaagtgate ctctgcctc tgctccaga gtagctgca 1080
 ctatgggcat gtgccaccac gcctggctaa catttgtatt gacctattta tttattgtga 1140
 tttatatctt tttttttttt tctttttttt ttttttacia aatcagaaat acttattttg 1200

50 <210> 53
 <211> 989
 <212> DNA
 <213> Human

55 <400> 53

60 aagccaccac tcaaaacttc ctatacattt tcacagcaga gacaagtga catttatttt 60
 tatgcctttc ttcctatgtg tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120
 gattcaatta gtccttgggc tggctgactg tgcaggagtc cagggagcct ctacaaatgc 180
 agagtgactc tttaccaaca taaaccctag atacatgcaa aaagcaggac ccttccctca 240
 ggaatgtgcc atttcagatg cacagcacc atgcagaaaa gctggaattt tccttggaa 300
 cgactgtgat agaggtgctt acatgaacat tgctactgtc tttctttttt tttgagacag 360
 gtttcgcttg tgcccaggct gagtgcattg cgtgatctca ctactgcaa ttccacctcc 420
 aggttcaagc atttctctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480
 65 ccggctaatt ttgtattttt gtagagatgg atttctccat ttggtcaggc ggtctcgaac 540
 cccaacctca gtgatctgcc acctcagcct cctaagtgtt ggattacagg atgagccacc 600

cgaccggcca ctactgtctt tctttgacct ttccagtttc gaagataaag aggaaataat 660
 ttctctgaag tacttgataa aatttccaaa caaacacat gtccacttca ctgataaaaa 720
 atttaccgca gtttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaaagag 780
 ttaagatttc ttcagcaaaa tagatgattc acatcttcaa gtcctttttg aaatcagtta 840
 5 ttaatattat tctttctca tttccatctg aatgactgca gcaatagttt tttttttttt 900
 tttttttttt ttgcgagatg gaatctcgct ctgtcgccca gcgggagtgc actggcgcaa 960
 gcccggtca ccgcaatctc tgccaccg

<210> 54
 10 <211> 250
 <212> DNA
 <213> Human

<400> 54
 15 catttcccca ttggtcctga tgttgaagat ttagttaaag aggctgtaag tcaggttcga 60
 gcagaggcta ctacaagaag tagggaatca agtccctcac atgggctatt aaaactaggt 120
 agtggtggag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180
 aaagggcatt ctttaggaac tgcattctgt aaccacacc ttgatccaag agctagggaa 240
 20 acttcagtgt

<210> 55
 <211> 2270
 <212> DNA
 25 <213> Human

<400> 55

30 gcgccccga gcagcgccg cgccctccgc gccttctccg ccgggacctc gagcgaaaga 60
 ggccccgcgc ccgcccagcc ctgcctccc tgcccaccgg gcacaccgcg ccgccacccc 120
 gaccccgctc cgcacggcct gtccgctgca caccagcttg ttggcgtctt cgtcgccgcg 180
 ctgcgcccg gctaactctg cgcgccacaa tgagctccc catcgccagg gcgtcgct 240
 tagtcgtcac ccttctccac ttgaccaggc ttggcgtctc cacctgcccc gctgcctgcc 300
 actgccccct ggaggcgccc aagtgcgcgc cgggagtcgg gctggtccgg gacggctgcg 360
 35 gctgctgtaa ggtctgcgcc aagcagctca acgaggactg cagcaaacg cagccctgcg 420
 accacaccaa ggggctgga tgcaacttcg gcgccaagtc caccgctctg aaggggatct 480
 gcagagctca gtcagagggc agaccctgtg aatataactc cagaatctac caaacgggg 540
 aaagtttcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600
 40 ttctctgtg tccccaagaa ctatctctcc ccaacttggg ctgtcccaac cctcggtg 660
 tcaaagttac cgggcagtgc tgcgaggagt gggctgtgta cgaggatagt atcaaggacc 720
 catgtggaga ccagacggc ctcttggca aggagctggg attcgatgcc tccgaggtg 780
 agttgacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggctcc 840
 ctgttttttg aatggagcct cgcattctat acaaccctt acaaggccag aaatgtattg 900
 45 ttaaaacaac ttcatgttcc cagtgtcaa agacctgtg aactggtatc tccacacgag 960
 ttaccaatga caacctgag tgccgccttg tgaaagaaac ccggatttgt gaggtgccc 1020
 ctgtgtgaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080
 aatccccga accagtcagg ttacttacg ctggatgttt gagtgtgaag aaataccggc 1140
 ccaagtactg cggttcctgc gtggacggc gatgctgcac gccccagctg accaggactg 1200
 50 tgaagatgag gttccgctgc gaagatggg agacattttc caagaacgct atgatgatcc 1260
 agtcctgcaa atgcaactac aactgcccgc atgccaatga agcagcgttt ccttctaca 1320
 ggctgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380
 cctagacaaa caaggagaa gagtgtcaga atcagaatca tggagaaaat gggcgggggt 1440
 ggtgtgggtg atgggactca ttgtagaaag gaagccttgc tcattcttga ggagcattaa 1500
 55 ggtatttcga aactgccaag ggtgctggtg cggatggaca ctaatgcagc cacgattgga 1560
 gaatactttg cttcatagta ttggagcaca gttactgct tcattttgga gcttgtggag 1620
 ttgatgactt tctgttttct gtttgaat tatttgctaa gcatattttc tctaggcttt 1680
 tttccttttg ggttctaca gtcgtaaaag agataataag attagtgtga cagtttaaag 1740
 cttttattcg tcttttgaca aaagtaaatg ggagggcatt ccatccctc ctgaaggggg 1800
 60 aactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860
 ggtgttttaa gactgaatgt tttatttatc aaatgtagc ttttggggag ggaggggaaa 1920
 tgtaatactg gaataatttg taaatgattt taattttata ttcagtgaag agattttatt 1980
 tatggaaata accatttaat aaagaaatat ttacctaata tctgagtgtg tgccattcgg 2040
 tatttttaga ggtgctccaa agtcattag aacaacctag ctcacgtact caattattca 2100
 aacaggactt attgggatac agcagtgaat taagctatta aaataagata atgattgctt 2160
 65 ttataccttc agtagagaaa agtcttttga tataaagtaa tgtttaaaaa acatgtattg 2220
 aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa

<210> 56
<211> 1636
<212> DNA
5 <213> Human

<400> 56

```
10 cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaagggg 60
   agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120
   cagtttgatt ggaagtccag ctgtgaaacc tggagcgctg ccttctcccc agatggctcc 180
   tggtttgctt ggtctcaagg aactgcatc gtcaaactga tcccctggcc gttggaggag 240
   cagttcatcc cttaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaaggg 300
   cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360
15 agcccgtagc cttccccacc cagcaggaag ctctgggcac gccaccaccc ccaagtgcc 420
   gatgtctctt gcctggttct tgctacggga ctcaacgatg ggcagatcaa gatctgggag 480
   gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
   agcttcacac ccagtggcag tttgattttg gtctccgctg cacgggataa gactcttcgc 600
   atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcggggcca cctgcagtgg 660
20 gtttactgct gttccatctc cccagactgc agcatgctgt gctctgcagc tggagagaag 720
   tcggctcttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
   agcagtgttg tctcttgtga cttctcccc gactctgccc tgcttgtcac ggcttcttac 840
   gataccaatg tgattatgtg ggacccctac accggcgaaa ggctgaggtc actccaccac 900
   acccaggttg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
25 tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
   tggggccctg aactgaaaac tcccattgca tttgctccta tgaccaatgg gctttgtctg 1080
   acatttttcc cacatgggtg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
   tggacagctc ctagggtcct gtcctcactg aagcacttat gccggaaaag ccttcgaagt 1200
   ttcttaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagttcctc 1260
30 acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaaatcgt 1320
   cctgtcaaag ggagttgctg gaataatggg ccaaactctt ggtcttgcac tgaaatagca 1380
   tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
   tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500
   aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
35 aagatggtga aggttgggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
   gaccctgtgc tgcgtt
```

<210> 57
<211> 460
40 <212> DNA
 <213> Human

<400> 57

```
45 ccattgtgtg atgagagaga gagagattgg gagggagagg gagctcacta gcgcataatg 60
   gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120
   tggaatgagc taaagcagcc gcctgggggtg ggaggccgag cccatttgta tgcagcaggg 180
   ggcaggagcc cagcaaggga gcctccattc ccaggactct ggagggagct gagaccatcc 240
   atgcccgcag agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300
50 aactgaggct gggaagtcac atagcaagtg actggcagag ctgggactgg aaccaacca 360
   gcctcctaga ccacggttct tccatcaat ggaatgctag agactccagc caggtgggta 420
   ccgagctcga attcgtaatc atggtcatag ctgtttcctg
```

<210> 58
<211> 1049
55 <212> DNA
 <213> Human

<400> 58

```
60 atctgatcaa gaatacctgc cctggtcact ctgcggatgt ttctgtccac ttgttcacat 60
   tgaggaccaa gatatccttt tttacagagg cacttggttcg gtctaacaca gacacctcca 120
   tgacgacatg ctggctcaca ttttgagtt ctgcagaagt cccctccca gcctggacta 180
   cagcgact ttcccgtagg ggtgcagtag ccgtttcgac agagcctgga gcaacttgaa 240
65 gtcagtgtct gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
   ggatctacaa tttttagtag ttttccattg tgagtctggg tcatactttt actgcttgat 360
```

5 aaaaatgtaaa cttcacctag ttcattcttct ccaaattccca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
 ggacttttgc ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatctttctg actggcagcc ccggtatata aatccaccaa ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tgggtcactt tcataatctt tcccccttat tatctgtaga 660
 attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctggtt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
 10 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 aacccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaaccggt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020
 acttcaagaa agactctggc tgttctcaa

 15 <210> 59
 <211> 747
 <212> DNA
 <213> Human

 20 <400> 59

 tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaatata atgtatcata ccaaccaag taaaccaagt acaaaaaata ttcataataa 180
 25 gttgttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
 ctctgtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360
 aaagaagccc ctggcacaaa agattccagt gccctgaag aggtccctt cctcctgtgg 420
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
 30 ccaattcaat gccacaccta ctggttacc tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccggtgt ttgtctcgaa gggctccaca 660
 gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgcgaattta gtagtaatag cggccgc

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.